 
 
     
 
 
 
 
 
 
Official Title : A Randomized, Double -Blind, Placebo  controlled, Global Phase 3 Study of Edasalonexent  
in Pediatric Patients with Duchenne Muscular Dystrophy  
 
NCT Number : NCT0 3703882  
 
Applicant/MAH:  Catabasis  Pharmaceutical s Inc. 
 
Version Date : 16 April 2020  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
&OLQLFDO7ULDO3URWRFR O&$7 $SULO
&RQILGHQWLDODQG3URSULHWDU\ &/,1,&$/678'<35272&2/
&$7 
$5$1'20,=(''28%/(%/,1'3/$&(%2
&21752//('*/2%$/ 3+$6(678'<2)
('$6$/21(;(17,13(',$75,&3$7,(176:,7+
'8&+(11(086&8/$5'<67523+<
6SRQVRU &DWDEDVLV3KDUPD FHXWLFDOV,QF
+LJK6WUHHWWK)ORRU
%RVWRQ0$7HO )D[ 
3URGXFW (GDVDORQH[HQW&$7
,1'1XPEHU 
(XGUD&71XPEHU 
3URWRFRO9HUVLRQ 3URWRFRO$PHQGPHQW
2ULJLQDO3URWRFRO-XO\
9HUVLRQ'DWH $SULO
&21),'(17,$/
7KHFRQILGHQWLDOLQIRUPDWLRQLQWKHIROORZLQJGRFXPHQWLVSURYL GHGWR\RXDVDQ,QYHVWLJDWRUSRWHQWLDO
,QYHVWLJDWRURUFRQVXOWDQW IRUUHYLHZE\\RX\RXUVWDIIDQG DSSOLFDEOH,QVWLWXWLRQDO5HYLHZ
%RDUG,QGHSHQGHQW(WKLFV&RPPL WWHHRUUHJXODWRU\+HDOWK$XWKRUL W\7KHLQIRUPDWLRQFRQWDLQHGKHUHLQ
VKRXOGQRWEHGLVFORVHGWRRWKHUVZLWKRXWZULWWHQDXWKRUL]DWLR QIURP&DWDEDVLV3KDUPDFHXWLFDOV,QFPI
PI
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 2  
  
 Investigatorâ€™s Agreement  
 
This protocol was designed and will be conducted, recorded, and reported in accordance with the Protocol and 
in compliance with the principles of Good Clinical Practice (GCP ), and any other applicable regulatory 
requirements .  GCP principles are stated in â€œGuidance for Good Clinical Practice,â€ International Council for 
Harmonisation ( ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use. 
I have read and agree to abide by the requirements of this protocol. 
  
Principal Investigator Signature Date  
  
  
Principal Investigator Name ( please print or type )  
 
 
PI
PI
PI
PI
&OLQLFDO7ULDO3URWRFR O&$7 $SULO
&RQILGHQWLDODQG3URSULHWDU\ 352&('85(6,1&$6(2)(0(5*(1&<

7DEOH (PHUJHQF\&RQWDFW,QIRUPDWLRQ
5ROHLQ6WXG\ 1DPH &RQWDFW,QIRUPDWLRQ
&OLQLFDO6WXG\0DQDJHU 
6HQLRU&OLQLFDO5HVHDUFK$VVRFLDWH
&DWDEDVLV3KDUPDFHXWLFDOV,QFRIILFH
PRELOH

&OLQLFDO6WXG\/HDGHU 0+3
9LFH3UHVLGHQW&OLQLFDO2SHUDWLRQV
&DWDEDVLV3KDUPDFHXWLFDOV,QFRIILFH
PRELOH

6WXG\0HGLFDO0RQLWRU 0%%6
0HGLFDO0RQLWRU
2USKDQ5HDFK/WGPRELOH

6SRQVRU0HGLFDO0RQLWRU 0'3K'
&KLHI0HGLFDO2IILFHU
&DWDEDVLV3KDUPDFHXWLFDOV,QFRIILFH
PRELOH

3KDUPDFRYLJLODQFH 
+HDGRI3KDUPDFRYLJLODQFHDQG6DIHW\
2USKDQ5HDFK/WGRIILFH
GLUHFW
PRELOH
ID[


7ROO)UHH1XPEHUV
*HUPDQ\ 
6ZHGHQ 
,VUDHO ,UHODQG 
$XVWUDOLD 
&DQDGD 
86$ PI
PI
PIPI
PI
PI
PI
PI
PI
PI
PI
PI
PI
PI
PI
PI
PI
PI
PI
PI
PI
PI
PIPI
PI
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 5 1. SYNOPSIS  
Name of Sponsor/Company:  
Catabasis Pharmaceuticals, Inc.  
Name of Investigational Product:  
Edasalonexent 
Name of Active Ingredient:  
Edasalonexent 
Title of Study:  
A Randomized, Double-Blind, Placebo -Controlled, Global Phase 3 Study of Edasalonexent in Pediatric 
Patients with Duchenne Muscular Dystrophy  
Phase of Development:  3 
Objectives:  
Primary  
â€¢ To assess the efficacy of edasalonexent as measured by change from Baseline (CFB) on North Star 
Ambulatory Assessment (NSAA) Total Score in pediatric patients with Duchenne muscular 
dystrophy ( DMD)  
Secondary  
â€¢ To assess the safety and tolerability of edasalonexent in pediatric patients with DMD  
â€¢ To assess the effects of edasalonexent on physical function as measured by the 10- meter walk/run 
test (10M WT) , time to stand from supine,  and the 4 -stair climb  in pediatric patients with DMD  
Methodology:  
This is a randomized, double -blind, placebo-controlled, Phase 3, multisite study of edasalonexent in pediatric 
patients with DMD.  Approximately 126  patients will be enrolled.   
Eligible patients will be ambulatory boys from â‰¥4.0 to <8.0 years of age with a confirmed diagnosis of DMD 
who have not used steroids within 24  weeks prior to treatment initiation (Day  1).   
As shown in the figure below, the study includes a 52-week, double- blind, placebo-controlled period 
comparing 1 dose level of edasalonexent with placebo, followed by a 2- week follow -up.  
Following completion of the treatment period and Primary Endpoint evaluation, patients may elect to 
continue in the open -label extension study, pending approval by appropriate ethics committees and regulatory 
authorities .  Patients who choose not to participate should complete the safety follow -up within 2 weeks.  
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 6 CAT -1004-301 â€“ Overview of Study Design  
 
Double -Blind Placebo -Controlled Study  
Following a Screening period to determine eligibility, approximately 126 patients will be randomized 2:1 to 
receive edasalonexent 100  mg/kg/day (administered as approximately 33 mg/kg 3 times per day [TID ]) or 
placebo in double -blind fashion daily for 52 weeks.  Randomization will be stratified by Baseline age 
(â‰¤6.0 years or > 6.0 years) , time to stand from supine (â‰¤5 seconds or >5  seconds), treatment with eteplirsen 
(yes or no) , and region  (North America  or Europe/ Asia/ Australia ).  If siblings are enrolled,  they will be 
assigned to the same treatment group.  
Screening procedures should be performed within 4 weeks prior to the start of treatment on Day  1.  At the 
discretion of the Investigator, informed consent, collection of medical history and demographic data, and collection of laboratory Screening assessments may be completed remotely by a qualified medical professional at an alternative site setting.   
After Screening, eligible patients will complete Baseline procedures and begin receiving study drug 
(edasalonex ent or placebo) on Day 1.  Study drug will be orally administered as soft- gel capsules in divided 
doses taken with food containing at least 8 grams of fat.  Patients and their families will be provided with 
written and verbal instructions for study drug administration, and subsequent doses will be administered remotely, except for on scheduled site visits as specified in the Schedule of Assessments (SOA).   
Patients will have sit e visits approximately every 13 weeks with site calls in between as specified in the SOA.  
The efficacy  and safety of edasalonexent will be assessed at the timepoints specified in the SOA.   
Efficacy assessments will include:  the NSAA; timed function tests (TFTs) including the 10MWT , time to 
stand from supine, and the 4- stair climb; muscle strength testing; Performance of Upper Limb (PUL) entry 
item assessment ; and assessment of health -related physical functioning as measured by the PODCI. 
Safety assessments will include collection of adverse events (AEs), serious adverse events (SAEs),  growth 
parameters,  vital  signs, physical examinations, clinical laboratory testing (including chemistry, hematology, 
and urinalysis), assessment of adrenal function (adrenocorticotrophic hormone [ACTH] and cortisol levels), 
and electrocardiogram (ECG).   
For analysis of pharmacokinetics ( PK), blood samples will be obtained for determination of edasalonexent 
and its metabolite  concentrations.   
Additionally, blood samples will be drawn to evaluate gene expression, micro -RNA,  and protein biomarkers 
that might predict the course of disease and/or responses to treatment . 
Additional cardiac ECG monitoring will be performed via a wearable cardiac monitoring device if approved 
for use in the participating country.  

Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 7 Lateral thoracolumbar spine  radiography and dual energy X -ray a bsorptiometry (DXA) scan will be 
performed  if approved by the appropriate governing bodies at each site or country. 
A safety follow -up should occur within 2 weeks of the last dose of study drug for collection of AEs.   
Inclusion / Exclusion Criteria:  
The eligibility criteria are designed to include only patients with an established diagnosis of DMD based on 
clinical, laboratory and genetic findings who are sufficiently well (both in terms of DMD and in terms of 
concomitant illness) to safely participate in study procedures and provide interpretable results.  
Inclusion Criteria  
A patient must meet all the following criteria to be eligible for this study.  
1. Written consent/assent by patient and/or legal guardian as per regional and/or Institutional Review 
Board ( IRB)/Independent Ethics Committee ( IEC) requirements  
2. Diagnosis of DMD based on a clinical phenotype with increased serum creatine kinase (CK) and 
documentation of mutation(s) in the dystrophin gene known to be associated with a DMD phenotype  
3. Male sex by birth  
4. Age â‰¥4.0 to <8.0 years (at the time of consent)  
5. Able to perform stand from supine without assistance in â‰¤ 10 seconds  
6. Able to perform the 10MWT and 4- stair climb  
7. Able to swallow placebo capsules at the Screening Visit 
8. Followed by a doctor or medical professional who coordinates Du chenne care on a regular basis and 
willingness t o disclose patient's study participation with medical professionals  
Exclusion Criteria  
A patient who meets any of the following criteria will be excluded from this study. 
1. Use of corticosteroids within 24 weeks prior to Day 1; use of inhaled , intranasal, and topical 
corticosteroids is permitted  
2. Use of an investigational dru g, idebenone, or dystrophin-focused therapy within 4  weeks or a period 
of 5 half -lives duration prior to Day  1 (whichever is longer ) or ongoing participation in any other 
therapeutic clinical trial.  Exception: Patients who have received at least 24  weeks of a stable dose of 
eteplirsen prior to Day 1, and expected to continue treatment, will be eligible.   
3. Use of the following within 4 weeks prior to Day  1: immunosuppressive therapy, warfarin, 
phenytoin, S-mephenytoin, cyclosporine, dihydroergotamine, ergotamine, fentanyl, alfentanil, 
pimozide, quinidine, sirolimus, tacrolimus , or paclitaxel  
4. Use of human growth hormone within 3 months prior to Day 1 
5. Documented positive hepatitis  B surface antigen, hepatitis C antibody, or human immunodeficiency 
virus (HIV) or a known risk factor for hepatitis such as a blood transfusion within 12 weeks prior to 
Day 1 
6. Hemoglobin <10.5 g/dL 
7. Abnormal gamma -glutamyl transferase (GGT) (>laboratoryâ€™s upper limit of normal [ULN]) 
8. Other prior or ongoing medical condition, known hypersensitivity to omega -3 fatty acids, physical 
findings, ECG findings, or laboratory abnormality (including but not limited to renal insufficiency or 
impaired hepatic function ) that, in the Investigatorâ€™s opinion, could adversely affect the safety of the 
patient, make it unlikely that the course of treatment or follow -up would be completed, or impair the 
assessment of study results (e.g., a gastrointestinal condition that would impair fat absorption) 
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 8 9. In the Investigatorâ€™ s opinion, unwilling or unable for an y reason (e.g., attentional or behavioral 
issues) to complete all study assessments and laboratory tests and comply with scheduled visits, 
administration of drug, and all other study procedures  
Note:  Patients may be re- tested or re -screened for eligibility after discussion with the Medical Monitor.  
Number of Patients:  
Approximately 126  patients will be enrolled in a 2:1 ratio to receive edasalonexent or placebo. 
Investigational Product, Dosage and Mode of Administration:  
Edasalonexent 100 mg/kg/day (administered as approximately 33 mg/kg TID).  The Sponsor will supply 
edasalonexent soft-gel capsules at a dose strength of 250 mg for oral administration; 100-mg capsules will be 
available should patients need a smaller size capsule to facilitate swallowing.  An Interactive Web Response 
System (IWRS) will determine each patientâ€™s weight -based dosing; the total daily dose will be within 80% to 
125% of each target dose.  Study drug will be taken with food containing at least 8 grams of  fat.  
Duration of treatment:  
The approximate duration of participation for each patient will be 58 weeks, including the 4- week Screening 
period, the 52- week  dosing period, and the 2- week  follow -up.   
Reference therapy, dosage and mode of administration:  
The Sponsor will supply placebo capsules for oral administration for assessment of swallowing prior to initiation of treatment and for administration during the study .  The appearance and administration of placebo 
will be identical to that of the investiga tional product. 
Criteria for evaluation: 
Efficacy  
The primary efficacy assessment is the NSAA Total Score.  
Secondary efficacy assessments will  include the following:  
â€¢ 10MWT 
â€¢ Stand from supine  
â€¢ 4-stair climb  
Additional efficacy assessments will include the following: 
â€¢ Muscle strength testing  
â€¢ PUL  entry item assessment  
â€¢ PODCI  Transfer and Basic Mobility scale  
Safety: 
Safety will be evaluated in terms of all treatment- emergent adverse events (TEAEs ) and SAEs, as well as 
physical examination, growth parameters, vital signs, clinical laboratory parameters (including chemistry, 
hematology and urinalysis ), adrenal function (ACTH and cortisol levels), and ECG .  Data from ECGs  will be 
locally read and cent rally evaluated.   
Additional Analyses : 
Plasma and urine PK will be evaluated in terms of concentrations of edasalonexent and its metabolites.   
PD evaluations may include  gene expression , micro -RNA,  and circulating protein biomarkers to evaluate the 
course of disease and/or responses to treatment . 
In addition, deoxyribonucleic acid ( DNA) samples may be collected to permit pharmacogenomics analysis 
of potential markers of clinical risk/benefit as well as drug metabolizing enzyme and/or transporter analysis.  
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 9 To measure heart rate and heart rate variability, additional cardiac monitoring will be performed for 
approximately  48 hours via a wearable cardiac monitoring device if approved for use in the participating  
country. 
To measure bone health, lateral thoracolumbar spine  radiography and DXA scan will  be performed  if 
approved by the appropriate governing bodies at each site or country .  Bone radiography will be locally read 
and centrally evaluated. 
Statistical Methods:  
Analysis Populations: 
The Randomized Population consists of all patients who are randomized into the study.  
The Safety Population will consist of all patients who receive at least 1 dose of study drug.  
The Full Analysis Population for efficacy analyses will be a modified intent to treat (mITT) population and 
will consist of all patients in the Randomized Population who receive at least 1 dose of study drug and provide at least 1 valid post Baseline NSAA efficacy assessment.   
The Per Protocol (PP) Population will consist of all patients in the Full Analysis Population who complete the study, without any significant protocol violations.   
The PK Population will consist of all patients in the Safety Populat ion who receive at least 1  dose of 
edasalonexent and have at least 1 measured  plasma  concentration.   
Other analysis populations may be defined in the statistical analysis plan (SAP).  
General Considerations: 
Descriptive characteristics for continuous variables will be summarized using mean, median, standard 
deviation, minimum and maximum values.  For categorical variables, the number and percentage of patients 
(or observations) will be reported.   
Unless other wise defined for a particular endpoint, a patientâ€™s b aseline value is the last measurement prior to 
initiation of study drug. Demographics, Baseline characteristics, and DMD -specific medical history will be listed by patient, and 
summarized by treatment gr oup.   
Results of efficacy assessments will be listed by patient, and summarized by treatment group and timepoint as 
applicable.  Descriptive statistics will be calculated for efficacy data as well as for CFB and differences 
between groups as applicable.   
Results of safety assessments will be listed by patient, and summarized by treatment group and timepoint as 
applicable.  Descriptive statistics will be calculated for safety assessments by treatment group and timepoint 
as applicable.  AEs will be coded us ing the  Medical Dictionary for Regulatory Activities (MedDRA
Â®) 
dictionary and will be categorized by system organ class and preferred term.  Abnormal clinical laboratory values will be identified as outside (above or below) the normal range and will be evaluated for clinically 
notable abnormalities.  Reference (normal) ranges for laboratory parameters will be included in the clinical 
study report.  Shift tables will be implemented as applicable.  Concomitant medications will be listed by 
treatment and coded  using the World Health Organization (WHO) Drug dictionary.  Medical history will be 
listed and coded by patient using the MedDRA
Â® dictionary.  
Results of PK and PD assessments will be listed by patient and summarized by treatment group and timepoint 
as applicable.  
Efficacy Endpoints and Analyses: 
The primary efficacy endpoint will be the CFB in t he NSAA Total Score at Week 52 .  
The CFB in NSAA Total Score  will be analyzed using a mixed -model repeated- measures (MMRM) analysis 
of covariance (ANCOVA) , impleme nted using SASÂ® Proc Mixed .  The factors in the model will be Baseline 
age (â‰¤ 6.0 years or > 6.0 years), time to stand from supine (â‰¤5 seconds or >5 seconds), region (North America 
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 10 or Europe /Asia/Australia ), visit, treatment group, Baseline value, Baseline value by visit, and treatment group 
by visit.   
The primary analysis will test the treatment difference at Week 52 via the MMRM model  at the 2 -sided 0.05 
level . The primary efficacy analysis will be performed on the Full Analysis Population with exclusions that 
may be defined in the SAP, such as excluding patients receiving treatment with eteplirsen.  
Secondary efficacy endpoints will include the CFB on the following:  
â€¢ 10MWT speed  
â€¢ Stand from supine speed  
â€¢ 4-stair climb speed  
The secondary efficacy endpoints will be analyzed in a similar manner to the primary efficacy endpoint 
analysis.   
Additional efficacy endpoints will include CFB on  the following: 
â€¢ Muscle strength testing  
â€¢ PUL  entry item assessment  
â€¢ PODCI Transfer and Basic Mobility scale  
Determination of Sample Size 
Approximately 126  patients will be  randomized  to either edasalonexent or placebo in a 2:1 ratio.  Based on 
Phase 1/2 data of changes in NSAA in this age group, an effect size of 0.625 is assumed.  With this effect 
size, and assuming a dropout rate of approximately 20% , the study ha s approximately 80% power to show a 
difference between the treatment groups at a 2 -sided type I error rate of 0.05.   
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 11 TABLE OF CONTENTS  
SPONSORâ€™S AGREEMENT  .......................................................................................................... 3  
PROCEDURES IN CASE OF EMERGENCY  ............................................................................... 4  
1. SYNOPSIS  ................................................................................................................... 5  
TABLE OF CONTENTS  .............................................................................................................. 11  
LIST OF TABLES  ........................................................................................................................ 15  
LIST OF FIGURES  ....................................................................................................................... 15  
LIST OF ABBREVIATIONS AND DEFINITIONS OF  TERMS  ............................................... 16  
2. INTRODUCTION  ...................................................................................................... 18  
2.1. Summary of Edasalonexent Nonclinical Data ........................................................... 19  
2.2. Summary of Edasalonexent Clinical Experience ....................................................... 20  
2.3. Dose Selection Rationale  ........................................................................................... 21  
3. TRIAL OBJECTIVES  ............................................................................................... 22  
3.1. Primary  ....................................................................................................................... 22  
3.2. Secondary  ................................................................................................................... 22  
3.3. Overall Study Design ................................................................................................. 22  
3.3.1.  Double- Blind Placebo -Controlled Study Design ....................................................... 23  
3.3.2.  Study Conduct during the COVID-19 Pandemic ....................................................... 23  
3.3.3.  Completion of a Patientâ€™s Participation in the Study and Overall Study 
Completion  ................................................................................................................. 24  
3.3.3.1.  Completion of a Patientâ€™s Participation in the Study  ................................................. 24  
3.3.3.2.  Premature Patient Discontinuation from the Study  .................................................... 24  
3.3.3.3.  Overall Study Completion .......................................................................................... 24  
3.4. Discussion of Study Design, Including Choice of Control Group ............................. 24  
4. PATIENT POPULATION AND SELECTION  ......................................................... 27  
4.1. Inclusion Criteria  ........................................................................................................ 27  
4.2. Exclu sion Criteria  ....................................................................................................... 27  
5. TREATMENTS  ......................................................................................................... 29  
5.1. Treatments Administered  ........................................................................................... 29  
5.1.1.  Double- Blind Placebo -Controlled Treatment ............................................................ 29  
5.1.2.  Investigational Product(s) Description ....................................................................... 29  
5.1.3.  Packaging and Labeling ............................................................................................. 29  
5.1.4.  Storage ........................................................................................................................ 29  
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 12 5.1.5.  Preparation and Administration ................................................................................. 29  
5.2. Dosing Considerations ............................................................................................... 30  
5.2.1.  Dose Selection Rationale  ........................................................................................... 30  
5.2.2.  Dose Modification or Reduction ................................................................................ 30  
5.2.3.  Safety Monitoring ...................................................................................................... 30  
5.2.4.  Treatment Compliance  ............................................................................................... 30  
5.2.5.  Treatment Discontinuation  ......................................................................................... 30  
5.3. Prior and Concomitant Medications and Therapeutic Procedures ............................. 30  
5.4. Method of Assigning Patients to Treatment ............................................................... 31  
5.5. Blinding and Randomization ...................................................................................... 31  
5.5.1.  Blinding and Randomization ...................................................................................... 31  
5.5.2.  Scheduled Unblinding ................................................................................................ 32  
5.5.3.  Emergency Unblinding .............................................................................................. 32  
6. STUDY ASSESSMENTS  .......................................................................................... 33  
6.1. Study Schedule of Events ........................................................................................... 33  
6.2. Screening and Baseline Assessments and Start of Treatment  .................................... 33  
6.3. Efficacy Assessments  ................................................................................................. 33  
6.3.1.  North Star Ambulatory Assessment (NSAA)  ............................................................ 33  
6.3.2.  Timed Function Testing ............................................................................................. 34  
6.3.3.  Muscle Strength Testing ............................................................................................ 34  
6.3.4.  Performance of Upper Limb (PUL) Scale  ................................................................. 34  
6.3.5.  The Pediatric Outcomes Data Collection Instrument (PODCI)  ................................. 35  
6.3.6.  Assessor Training and Ensuring Compliance with Protocol- Specified Test -
Administration.  ........................................................................................................... 35  
6.4. Safety Assessments  .................................................................................................... 35  
6.4.1.  Physical Examination and Growth Parameters  .......................................................... 36  
6.4.2.  Vital Signs  .................................................................................................................. 36  
6.4.3.  Clinical Laboratory Tests  ........................................................................................... 36  
6.4.4.  Electrocardiogram  ...................................................................................................... 36  
6.4.5.  Concomitant Medications and Therapies ................................................................... 37  
6.5. Pharmacokinetic Assessments  ................................................................................... 37  
6.6. Pharmacodynamic Assessments  ................................................................................. 37  
6.7. Cardiac Monitoring .................................................................................................... 37  
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 13 6.8. Bone Evaluations ....................................................................................................... 38  
6.9. Study Drug Acceptability ........................................................................................... 38  
6.10.  Total Volume of Blood Collected .............................................................................. 38  
7. ADVERSE EVENTS AND ADVERSE EVENT REPORTI NG .............................. 39  
7.1. Timeframe for Collection of Adverse Events ............................................................ 39  
7.1.1.  Adverse Events Occurring Prior to Study Treatment ................................................ 39  
7.1.2.  Adverse Events Occurring After Study Treatment  .................................................... 39  
7.1.3.  Adverse Events Occurring Following Patient Discontinuation of Treatment ........... 39  
7.2. Definitions  .................................................................................................................. 39  
7.2.1.  Definition of an Adverse Event .................................................................................. 39  
7.2.2.  Definition of a Serious Adverse Event ....................................................................... 40  
7.3. Evaluation of Adverse Events/Serious Adverse Events ............................................. 40  
7.3.1.  Relationship to Study Treatment ................................................................................ 40  
7.3.2.  Severity Grading of Adverse Event Scoring .............................................................. 40  
7.3.3.  Outcome ..................................................................................................................... 41  
7.3.4.  Action Taken Regarding the Investigational Product ................................................ 41  
7.4. Recording of Adverse Events/Serious Adverse Events ............................................. 42  
7.5. COVID-19 Adverse Events and/or Serious Adverse Events ..................................... 42  
7.6. Reporting of Serious Adverse Events ........................................................................ 42  
7.7. Follow-up of Adverse Events/Serious Adverse Events ............................................. 43  
7.8. Pregnancy Reporting .................................................................................................. 43  
7.9. Temporary or Persistent Dose Reductions ................................................................. 43  
7.10.  Monitoring of Abnormal Laboratory Values ............................................................. 43  
7.11.  Stopping Rules ........................................................................................................... 44  
7.12.  Restriction on the Lifestyle of Patients  ...................................................................... 44  
8. DATA COLLECTION, QUALITY ASSURANCE, AND MANAGEMENT  ......... 45  
8.1. Recording of Data ...................................................................................................... 45  
8.2. Data Quality Assurance .............................................................................................. 45  
8.3. Data Management  ...................................................................................................... 45  
8.4. Data Safety Monitoring Board ................................................................................... 45  
9. STATISTICAL METHODS AND PLANNED ANALYSES  ................................... 47  
9.1. General Considerations .............................................................................................. 47  
9.2. Determination of Sample Size  ................................................................................... 47  
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 14 9.3. Analysis Sets  .............................................................................................................. 47  
9.4. Demographics and Baseline Characteristics  .............................................................. 48  
9.5. Concomitant Medications .......................................................................................... 48  
9.6. Medical History  .......................................................................................................... 48  
9.7. DMD-Spe cific Medical History  ................................................................................. 48  
9.8. Patient Disposition  ..................................................................................................... 48  
9.9. Study Treatment Usage and Compliance ................................................................... 48  
9.10.  Efficacy Analyses  ....................................................................................................... 48  
9.10.1.  Primary Efficacy Endpoint ......................................................................................... 49  
9.10.2.  Secondary Efficacy Endpoints ................................................................................... 49  
9.10.3.  Controlling for Multiplicity  ........................................................................................ 49  
9.10.4.  Sensitivity Analyses of the Primary and Secondary Efficacy Endpoints .................. 49  
9.10.5.  Additional Efficacy Endpoints ................................................................................... 49  
9.11.  Pharmacokinetic Analyses  ......................................................................................... 50  
9.12.  Safety Analyses  .......................................................................................................... 50  
9.12.1.  Physical Examination, Growth Parameters, Electrocardiograms, and Vital Signs .... 51  
9.12.2.  Clinical Laboratory Tests  ........................................................................................... 51  
9.12.3.  Adverse Events  ........................................................................................................... 51  
9.13.  Pharmacodynamic Analyses  ...................................................................................... 51  
9.14.  Cardiac Monitoring .................................................................................................... 52  
9.15.  Bone Evaluations ....................................................................................................... 52  
9.16.  Other Statistical Issues  ............................................................................................... 52  
9.16.1.  Missing or Invalid Data .............................................................................................. 52  
9.16.2.  Multisite Issues  ........................................................................................................... 52  
9.16.3.  Subgroup Analyses ..................................................................................................... 52  
10. SPECIAL REQUIREMENTS  AND PROCEDURES  ............................................... 53  
10.1.  Institutional and Ethics Review  ................................................................................. 53  
10.2.  Changes to the Conduct of the Study or Protocol ...................................................... 53  
10.3.  Investigatorâ€™s Responsibilities  ................................................................................... 53  
10.3.1.  Patient Informed Consent ........................................................................................... 53  
10.3.2.  Case Report Forms  ..................................................................................................... 53  
10.3.3.  Record Retention  ........................................................................................................ 54  
10.3.4.  Monitoring .................................................................................................................. 54  
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 15 10.3.5.  Study or Site Termination  .......................................................................................... 54  
10.3.6.  Investigational Product Control ................................................................................. 55  
10.3.6.1.  Receipt of Investigational Product ............................................................................. 55  
10.3.6.2.  Disposition of Unused Investigational Product .......................................................... 55  
10.3.6.3.  Product Handling and Complaints Reporting ............................................................ 55  
10.3.7.  Disclosure of Data  ...................................................................................................... 55  
10.3.8.  Confidentiality and Data Privacy ............................................................................... 55  
11. REFERENCES  ........................................................................................................... 57  
APPENDIX 1.  SCHEDULE OF ASSESSMENTS  .................................................................... 60  
APPENDIX 2.  POTENTIAL MODIFICATIONS TO THE SCHEDULE OF 
ASSESSMENTS DURING THE COVID- 19 PANDEMIC  ...................................... 62  
APPENDIX 3.  LIST OF CLINICAL LAB ORATORY ASSESSMENTS  ................................ 65  
APPENDIX 4.  STUDY DRUG QUESTIONNAIRE  ................................................................. 66  
APPENDIX 5.  PEDIATRIC OUTCOMES QUESTIONNAIRE (PODCI)  ............................... 68  
 
LIST OF TABLES  
Table 1:  Emergency Contact Information .................................................................................. 4  
Table 2:  Prohibited Prior and Concomitant Medications ......................................................... 31  
 
LIST OF FIGURES  
Figure 1:  CAT -1004-301 â€“ Overview of Study Design ............................................................ 22  
 
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 16 LIST OF ABBREVIATION S AND DEFINITIONS OF TERMS  
The following abbreviations and terms are used in this study protocol. 
Abbreviation  Definition  
10MWT  10-meter walk/run test  
ACTH  adrenocorticotropic hormone  
AE adverse event  
ALT  alanine aminotransferase  
ANCOVA  analysis of covariance  
AST  aspartate aminotransferase  
BID twice a day  
BMI  body mass index  
CA Competent Authorities  
CFB change from Baseline  
Clast last quantifiable plasma concentration  
Cmax maximum plasma concentration  
CK creatine kinase  
DHA  docosahexaenoic acid 
DMD Duchenne muscular dystrophy 
DNA  deoxyribonucleic acid 
DSMB  Data Safety Monitoring Board 
DXA  dual energy X- ray absorptiometry  
ECG  electrocardiogram 
eCRF  electronic Case Report Form  
EDC  electronic data capture 
ET early termination  
GCP  Good Clinical Practice  
GGT  gamma -glutamyl transferase  
GRMD golden retriever muscular dystrophy 
HEENT  head, eyes, ears, nose, throat  
ICH International Council for Harmonisation  
IEC Independent Ethics Committee  
IRB Institutional Review Board 
LPS lipopolysaccharide   
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 17 Abbreviation  Definition  
MedDRA  Medical Dictionary for Regulatory Activities 
MMP9  matrix metalloproteinase 9  
MMRM  mixed -model repeated -measures  
MRI  magnetic resonance imaging  
MuRF1  muscle RING finger protein 1 
n sample size  
NCS  not clinically significant  
NF-ÎºB nuclear factor kappa light chain enhancer of activated B cells  
NOAEL  no-observed -adverse- effect level  
NSAA  North Star Ambulatory Assessment  
PD pharmacodynamic 
PK pharmacokinetic(s) 
PODCI  Pediatric Outcomes Data Collection Instrument  
PUL  Performance of Upper Limb  
RNA  ribonucleic acid  
SAE  serious adverse event  
SAP Statistical Analysis Plan  
SDHM  Study Drug Handling Manual  
SOA Schedule of Assessments  
SOC  System Organ Class  
SOCS3  suppressor of cytokine signaling 3 
SRM  Study Reference Manual 
TID 3 times per day 
TEAE treatment emergent adverse event  
TFT Timed Function Test 
TNFÎ± tumor necrosis factor alpha  
ULN upper limit of normal 
WHO World Health Organization 
 
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 18 2. INTRODUCTION   
The purpose of this multisite, Phase 3 study is to confirm  the efficacy  and safety  of edasalonexent  
(CAT -1004) on  ambulatory male  pediatric patients with  a confirmed diagnosis of Duchen ne muscular 
dystrophy ( DMD).  The  study is  a 52-week, double-blind, placebo-controlled study comparing 
100 mg/kg/day of edasalonexent (administered as approximately 33 mg/kg 3 times per day [TID]) 
with placebo .   
Duchenne Muscular Dystrophy  
DMD is a progressively debilitating and ultimately fatal inherited neuromuscular disorder affecting 
approximately 1 in 3,500 to 5,000 live male births worldwide .  It is caused by mutations in the gene 
encoding dystrophin, a critical part of the protein complex that connects the cytoskeletal actin of a 
muscle fiber to the extracellular matrix .  In the absence of dystrophin, the stress of repeated muscle 
contractions damages the sarcolemma resulting in repeated cycles of cellular degeneration, progressively failing regeneration, and inflammation ( Blake, 2002; Emery, 2002) .  Over time, muscle 
is replaced by fibrotic tissue and fat.  Of note, while a lack of dystrophin is the primary cause of 
DMD, it is not sufficient for disease progression, as evidenced by the heterogeneity in disease 
progression among different muscles ( Porter, 2003 ; Hu, 2015) . 
Affected child ren are usually diagnosed between the ages of 3 to 5 years when they begin to show 
lordosis, waddling gait, toe walking, calf hypertrophy, and have difficulty climbing stairs.  By 8 years of age, most patients are losing the ability to rise from the floor and climb stairs, have an increasingly labored gait, and often fall while walking.  By 10 to 14 years of age, most are wheelchair -dependent .  
Upper limb, cardiac, and diaphragmatic muscles continue to progressively weaken during adolescence, and patients o ften require ventilation support in their teens.  In recent years, use of 
ventilation support and glucocorticoids have increased life span by several years ( Kohler, 2009) ; 
however, DMD still has an early mortality rate of 100%.   
There is no cure for DMD and those drug treatments that have recently been approved for the disease, 
i.e., ataluren, which received conditional approval in the Eu ropean Union, and eteplirsen 
(Exondys51â„¢) , which received accelerated approval in the United States, demonstrate limited 
efficacy and are appropriate for only a subset of patients.  Current standard of care guidelines include the administration of glucocor ticoids  (Birnkrant, 2018a ; Birnkrant, 2018b)
, which can delay the time 
to respirator dependence and t he onset of scoliosis, and improve performance on measures of clinical 
function in patients with DMD ( Manzur, 2009) .  However , they do not fully ameliorate symptoms or 
halt disease progr ession .  Moreover, their use is often limited by numerous side effects, including 
growth inhibition, delay of pubertal changes, weight gain, behavioral changes, osteoporosis resulting in fractures, Cushingoid facies and habitus, cataracts, and myopathy, a particularly serious concern for patients with DMD (Manzur, 2009; Schakman, 2009; Hanaoka, 2012 ).   
Thus, even though there are a handful of treatment options available, those options are inadequate and a significant need remains for safer and more effective treatments for patients affected by this fatal disease.  
Rationale for Edasalonexent as a Potential Therapy for the Treatment of DMD  
Edasalonexent, an orally administered small molecule containing covalently linked salicylic acid and docosahexaenoic acid ( DHA), synergistically leverages the ability of both compounds to 
intracellularly inhibit activated nuclear factor kappa light chain enhancer of activated B  cells 
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 19 (NF-ÎºB) to reduce NF- ÎºB-mediated inflammation and muscle degeneration and facilitate muscle 
regeneration ( Kopp, 1994; Yin, 1998; Cai, 2004; Zwart, 2010) .  Following its cellular uptake, 
edasalonexent is hydrolyzed into its constituents by endogenous fatty acid amide hydrolase (FAAH), 
simultaneously delivering salicylic acid and DHA to key intracellular targets where they significantly inhibit activated NF -ÎºB. 
In vitro, edasalonexent inhibits NF-ÎºB and downstream cytokines known to be increased in DMD (Vu, 2016) .  Edasalonexent inhibits lipopolysaccharide  (LPS)-stimulated pro -inflammatory gene 
expression ( TNF Î±, IL -6, IL -1Î², SOCS3, MMP9) in RAW264.7 macrophages and this effect is greater 
than that produced by DHA or the combination of DHA and salicylic acid.  In addition, studies in mouse C2C12 myotubes showed that edasalonexent blocks cytokine-induced reductions in MyoD to a greater degree than dexam ethasone and blunts cytokine-induced upregulation of MuRF1 and 
MMP9, both of which promote the degradation of key intracellular proteins and the extracellular matrix (Cai, 2004; Li, 2009) .  The se data are consistent with selective inhibition of activated NF -ÎºB 
by edasalonexent having a more positive and favorable effect on muscle degeneration and 
regeneration than that produced by the concomitant NF-ÎºB inhibition and activation of the 
glucocorticoid receptor by glucocorticoids.  
In vivo, edasalonexent inhibits NF-ÎºB, and has positive effects in the mdx  and golden retriever 
muscular dystrophy ( GRMD) models of DMD.  Edasalonexent reduced LPS- stimulated release of 
TNFÎ± levels in normal mice, and reduced muscle inflammation and muscle fiber degeneration, 
preserved muscle mass, and increased the number of regenerating fibers per field in the mdx mouse 
model of muscular dystrophy ( Hammers, 2016) .  Moreover, a single treatment with edasalonexent 
inhibited basal NF-ÎºB p65 deoxyribonucleic acid ( DNA) binding as well as LPS- stimulated NF -ÎºB 
p65 activity and induction of TNFÎ± protein in the GRMD dog model.  Similarly, administration of 
CAT -1041, a closely related analog of edasalonexent that differs only in the omega- 3 fatty acid 
moiety, significantly improved muscle endurance, increased muscle mass, and reduced fibrosis in the 
mdx mouse, and improved pulmonary function in the GRMD model of DMD. 
By reducing inflammation and muscle degeneration while simultaneously facilitating muscle 
regeneration, pharmacological inhibition of NF-ÎºB with edasalonexent has the potential to  provide 
disease-modifying benefits to patients of all mutations beyond those afforded by glucocorticoids, but 
without their negative side effects, which are largely independent of their anti- inflammatory 
properties ( Schacke, 2004 ; Newton, 2007) .   
2.1. Summary of Edasalonexent  Nonclinical Data  
In nonclinical studies, edasalonexent  demonstrated reduction of NF -ÎºB activation in  vitro and in vivo, 
and disease-modifying effects in 2  established animal models of DMD, the mdx  mouse and the 
GRMD models .  To support single- and repeat -dose oral administration in healthy subjects, 
edasalonexent  has been assessed in a series of nonclinical studies including safety pharmacology, 
genotoxicity, and general toxicity studies in rats and dogs, with durations of repeat dose oral 
administration  up to 6 and 9 months , respectively .   
Detailed information on all edasalonexent  nonclinical studies conducted to date can be found in t he 
Investigatorâ€™s Brochure. 
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 20 2.2. Summary of Edasalonexent  Clinical Experience  
Edasalonexent was  evaluated in three Phase 1 studies in adults ( Donovan, 2017) . Across the 
3 studies, 79 adult subjects  received  single doses of edasalonexent  up to 6000 mg and multiple doses 
up to 4000 mg/day for 14  days (~100 and 67 mg/kg/day, respectively), with no identified safety 
concerns .  Single-dose exposures of 2000 mg ( ~33 mg/kg) edasalonexent  significantly reduced 
ex vivo LPS -stimulated  NF-ÎºB activity  and NF- ÎºB p65 DNA binding, while 14 days of dosing with 
edasalonexent  reduced basal expression of  NF-ÎºB target genes  in patients with  type 2 diabetes with 
mild inflammation .   
Edasalonexent is currently being evaluated  in ambulatory boys with DMD from â‰¥4 to <8 .0 years of 
age at enrollment who are not receiving  corticosteroids in a multipart, Phase 1/2 clinical study , 
CAT -1004-201.  Phase 1 , which has been completed, was a 1 -week, open-label study to assess the 
safety and pharmacokinetics ( PK) of 3 sequential ascending doses (33, 67, or 100 mg/kg/day  
administered as 17 mg/kg twice daily [BID], 33 mg/kg BID, or 33 mg/kg TID) of edasalonexent 
under low- or high-fat conditions.  Results from Phase 1  indicate that 7 days  of treatment with 
edasalonexent  at doses up to 100 mg/kg/ day were safe and generally well tolerated . There were no 
serious adverse events (SAEs), discontinuations, or dose reductions, and the most common adverse 
events (AEs) were gastrointestinal, primarily  mild diarrhea .  Pharmacokinetic data collected showed 
daily exposures projected to be within the range observed in adults (on a mg/kg basis), with only modest dif ferences between dosing after a high - or low- fat meal  at the 67 mg/kg/day dose.  
Importantly, clinical exposure at 100 mg/kg/day was 4  times lower than exposures at the 
no-observed-adverse- effect level ( NOAEL ) in the 13- week postnatal day  (PND) 21 rat study, and 
2 times lower than those at the NOAEL in the 13 -week dog study.  
Phase 2 , which has also been completed, included patients from P hase 1  as well as additional patients 
(total N  = 31) and  was a randomized, placebo -controlled  study to evaluate the efficacy, safety, PK, 
and PD of the 2 higher doses edasalonexent (67  and 100 mg/kg/day) over 12 weeks .  Both doses were 
safe and generally well tolerated .  There were no dose-dependent safety findings and, as in Phase 1 , 
the majority of  AEs were mild in nature and the most common treatment- related AEs were 
gastrointestinal, primarily mild and transient diarrhea.  There were no  treatment -related SAEs, drug 
discontinuations, or dose reductions, nor were there any concerning trends in chemistry, hematology, 
coagulation, or adrenal function assessments .  Edasalonexent plasma exposure s were consistent with 
those observed in P hase 1 .  The 100 mg/kg/day dose level dem onstrated numerical improvement 
versus placebo  across multiple efficacy measures, though not stat istically significant.  The 
67 mg/kg/day dose group had mixed efficacy results compared with both the 100 mg/kg/day dose group and placebo, which in each case were not statistically significant.   
In the open -label extension , which i
 s currently ongoing, al l patients  (including those who received 
placebo in Phase 2 ) were to receive open -label edasalonexent  at dose levels of 67 or 100 mg/kg for up 
to 124 weeks .  Based on results from Phase 2  and the recommendation of the Data Safety Monitoring 
Board (DSMB), all patients in the 67 mg/kg/day dose group were switched to the 100 mg/kg/day dose 
group (which was already ongoing at the time the P hase 2  results were analyzed ).   
In an interim analysis conducted with all data through December 31, 2017, patients on e dasalonexent 
at 100 mg/kg/day over 60 weeks of treatment show ed a slower decline in timed function test speeds 
(10-meter walk/run test [ 10MWT], 4- stair climb, and time to stand) and North Star Ambulatory 
Assessment ( NSAA) when compared to declines in the prior off- treatment control period.  In addition 
to the muscle function assessments, supportive changes in measures of muscle health were observed, 
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 21 consistent w ith positive edasalonexent treatment effects.  Four muscle enzymes (creatine kinase, 
alanine aminotransferase, aspartate aminotransferase and lactate dehydrogenase) were significantly 
lower compared to Baseline following 12 weeks of edasalonexent treatment and at later time points, consistent with a slowing of muscle degeneration and an improvement in muscle integrity.  A 
composite of magnetic resonance imaging ( MRI ) T2 rates of change in five lower leg muscles was 
also significantly improved through 48 wee ks of 100 mg/kg/day edasalonexent treatment compared to 
the off-treatment control period, consistent with a reduction of inflammation in the muscle. 
Improvements were also seen in rates of change in both soleus and vastus lateralis magnetic 
resonance spect roscopy ( MRS ) fat fraction through 48 weeks of edasalonexent treatment compared to 
the off- treatment control period , consistent with a reduction of fat  in the muscle .  Edasalonexent 
remained  well tolerated and no safety signals were observed. The most common adverse events, 
gastrointestinal, were typically mild and transient.  Based on emerging safety and efficacy data, all 
patients moved to 133 mg/kg/day (33/33/67 mg/kg in 3 divided doses) in the open- label extension . 
As of June 2018, 32 pediatric patients  had received up to 112 weeks of active dosing with 
edasalonexent at doses up to  133 mg/kg/day, with a total combined exposure of over 45 years,  with 
no safety concerns .  More detailed i nformation on clinical studies and potential clinical risks of 
edasalonexent  can be found in the Investigatorâ€™s Brochure.   
2.3. Dose Selection Rationale  
Selection of the 100 mg/kg/day dose of edasalonexent for this Phase 3 study is supported by interim 
results  from  the ongoing Phase 1/2 study of edasalonexent in same aged boys with DMD 
(CAT -1001-201), which showed: 
â€¢ The plasma exposure of edasalonexent at the NOAEL in the 26-week rat study (2000 mg/kg/day) is approximately 4-fold higher than that expected with the anticipated clinical 
dose utilized in CAT-1004-201 of 100 mg/kg/day.  The plasma exposure of edasalonexent 
at the NOAEL in the 13-week and 9 -month dog studies  (1000 mg/kg/day) is 
approximately 2-fold higher, than that expected with the anticipated clinical dose for this study of 100 mg/kg/day. 
â€¢ Treatment with edasalonexent at doses of 67 mg/kg/day for up to 47 weeks, at 
100 mg/kg/day for up to 84 weeks, and at 133 mg/kg/day for up to 32 weeks was  safe and 
generally well tolerated with no dose- dependent safet y findings, treatment- related SAEs, 
drug discontinuations, or dose reductions, and no concerning trends in chemistry, hematology, coagulation, or adrenal function assessments . 
â€¢ Treatment with 100  mg/kg/day edasalonexent resulted in numerical improvements across 
multiple efficacy measures  compared to placebo .  In contrast, the 67 mg/kg/day dose 
group had mixed efficacy results compared with both the 100 mg/kg/day dose group and 
placebo .  Compared to declines in the prior off- treatment control period, patients on 100 
mg/kg/day edasalonexent showed a slower decline in timed function test speeds and 
NSAA scores  over 60 weeks of treatment. 
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 22 3. TRIAL OBJECTIVES 
3.1. Primary  
â€¢ To assess the efficacy of edasalonexent as measured by change from Baseline (CFB) on 
NSAA Total Score  in pediatric patients with DMD  
3.2. Secondary  
â€¢ To assess the safety and tolerability of edasalonexent in pediatric patients with DMD  
â€¢ To assess the effects of edasalonexent on physical fun ction as measured by the 10MWT, 
time to stand from supine, and the 4 -stair climb  in pediatric patients with DMD  
3.3. Overall Study Design  
This is a randomized, double-blind, placebo-controlled, Phase 3, multisite study of edasalonexent in pediatric patients with DMD .  Approximately 126 patients will be enrolled .   
Eligible patients will be ambulatory boys â‰¥4.0 to <8 .0 years of age with a confirmed diagnosis of 
DMD who have not used steroids within 24 weeks prior to treatment  initiation (Day 1).  In regions 
where eteplirsen is approved or there is an established access program , patients who have received at 
least 24  weeks of treatment with eteplirsen  prior to Day  1 will be eligible  for the study. 
As shown in Figure 1, this is a 52-week, double-blind, placebo-controlled study comparing one dose 
level of edasalonexent with placebo .   
Following completion of the treatment period and Primary Endpoint evaluation, patients may elect to continue in the open-label extension study, pending approval by appropriate ethics committees and 
regulatory authorities.  Patients who choose not to participate should complet e the safety follow-up 
within 2  weeks  of the last dose of study drug. 
Figure 1: CAT -1004-301 â€“ Overview of Study Design 
 

Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 23 3.3.1. Double -Blind Placebo -Controlled  Study Design 
As shown in Figure 1, f ollowing a Screening period to determine eligibility, approximately 
126 patients will be randomized 2:1 to receive edasalonexent 100 mg/kg/day (administered as 
approximately 33 mg/kg TID ) or placebo in double-blind fashion daily for 52 weeks .  The exact 
capsule count per dose will be provided.  Randomization will be stratified  by Baseline age (â‰¤6.0 years 
or >6.0 years), time to stand from supine (â‰¤5 seconds or >5 seconds), treatment with eteplirsen (yes 
or no), and region (North America or Europe/ Asia/Australia ). If siblings are enrolled, they will be 
assigned to the same treatment group. 
All Screening  procedures will be performed within 4 weeks  prior to the start of treatment (Day 1).  At  
the discretion of the Investigator, informed consent, collection of medical history and demographic 
data, and collection of laboratory S creening  assessments may be completed remotely by a qualified 
medical professional  at an alternative site setting .   
After Screening, eligible p atients will complete Baseline procedures and begin receiving study drug 
(edasalonexent or placebo) on Day  1.  Study drug will be orally administered as soft- gel capsules in 
divided doses taken with food containing at least 8 grams of fat as detailed in Section  5.1.1.  Patients 
and their families will be provided with written and verbal instructions for study drug administration, and subsequent doses will  be administered remotely, except for on scheduled site visits as specified in  
the Schedule of Assessments (SOA) in  Appendix 1.  Nutritional guidance will be provided at 
Baseline.  Patient compliance with nutritional guidance will be confirmed throughout treatment.   
Efficacy  and safety will be assessed at  site visits at the timepoints specified in the SOA  in 
Appendix 1.  Efficacy assessments will include: the NSAA; timed function tests ( TFTs ) including the 
10MWT, time to stand from supine, and the 4- stair climb; muscle strength testing; the Performance of 
Upper Limb ( PUL ) scale; and assessment of physical functioning as measured by the PODCI .   
Safety assessments will include collection of AEs, SAEs, growth parameters (height and  weight), 
vital signs, physical examinations, clinical laboratory testing (including chemistry, hematology, and urinalysis), assessment of adrenal function (adrenocorticotrophic hormone [ACTH] and cortisol 
levels), and electrocardiogram ( ECG ).  To measure heart rate and heart rate variability, additional 
cardiac monitoring will be performed for approximately 48 hours via a wearable cardiac monitoring 
device if approved for use in the participating country. To measure bone health, lateral spin e 
radiography and dual energy X-ray absorptiometry ( DXA) scan will be performed if approved by the 
appropriate governing bodies at each site or country. 
For analysis of PK, blood and urine samples will be obtained for determination of edasalonexent and 
its metabolite  concentration s.  Blood samples will be drawn for analysis of PD. 
To assess ac ceptability and palatability of edasalonexent, caregivers will complete a study drug 
questionnaire. 
A safety follow-up should occur  within 2 weeks of the last dose of study drug for collection of AEs. 
3.3.2. Study Conduct during the COVID-19 Pandemic   
Ensuring the safety of patients is paramount especially during a pandemic so modifications have been 
made to the original study procedures and schedule of assessments to reduce the patientâ€™s risk or 
exposure to COVID -19 while ensuring the integrity of the study. Changes to the study visit schedule 
which should be considered, or deemed necessary per the local situation at each site during the 
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 24 COVID-19 pandemic are  captured in Appendix 2. Patients may not be able to come on-site for visits 
as specified in Appendix 1 or patients may be able to come on-site for visits however for a reduced 
amount of time to minimize risk or exposure to COVID-19, so considerations for modifying the 
schedule of assessments are captured in Appendix 2.        
Investigators must document how restrictions or institutional requirements during the COVID -19 
pandemic led to the changes in study conduct and duration of those changes and indicate which 
patients were impacted and how those patients were impacted.    
3.3.3. Completion of a Patientâ€™s Participation in the Study and Overall Study Completion  
3.3.3.1. Completion of a Patientâ€™s Participati on in the Study  
The length of a patientâ€™s participation in the study will be from the time the informed consent form is 
signed through the Week  52 visit.  A patient will be considered to have completed the study when 
they have completed the Week  52 assessments.  Patients  who do not participate in the open- label 
extension study will be considered to have completed the study after  they complete the safety follow-
up.  
3.3.3.2. Premature Patient Discontinuation from the Study  
Parents/guardians and patients (as applicable according to site and regional regulations) are free to 
withdraw consent and/or discontinue participation in the study at any time, without prejudice to 
further treatment .  A patientâ€™s participation in the stu dy may also be discontinued at any time at the 
discretion of the Investigator, Medical Monitor, or Sponsor. 
The reasons indicated in Section  5.2.5 for withdrawing a patient from treatment may also be 
justifiable reasons for the Investigator , Medical Monitor, or Sponsor to remove a patient from the 
study.  Patients also may be discontinued from the study if the study is terminated by the Sponsor ( see 
Section  10.3.5). 
Patients who are prematurely withdrawn from the study (i.e., those who leave the study prior to 
completing the Week  52 assessments) will be asked to complete  an early termination (ET) visit prior 
to their last dose of study drug and are not permitted to re-enroll in the study.   
Post-study SAEs will be reported according to Section  7.6.  A patient will be considered discontinued 
due to an AE if they discontinued due to any AE, regardless of whether  the AE is considered related 
to investigational product.  If the patient withdraws from the study due to an AE, the Investigator should arrange for the patient to be followed appropriately until the AE has resolved or stabilized (in the opinion of the Investigator). 
At the end of the patientâ€™s participation in the study, the Investigator will document the reason(s) for 
study discontinuation in the electronic case report form (eCRF ). 
3.3.3.3. Overall Study Completion 
The study will be considered complete when the last patient has completed  their last assessment . 
3.4. Discussion of Study Design, Including Choice of Control Group  
This is a Phase 3 study to evaluate the efficacy, safety, PK , and PD of edasalonexent in ambulatory, 
male, pediatric patients with a confirmed diagnosis of DMD.  This  is a randomized, double-blind, 
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 25 placebo -controlled study in which patients will receive either edasalonexen t or placebo daily for 
52 weeks .  
The rationale for the dose levels and dosing regimen used in the study is provided in Section  2.3. 
Population 
The studyâ€™s eligibility criteria are designed to include  only patients with an established diagnosis of 
DMD who are sufficiently well (both in terms of DMD and in terms of concomi tant illness ) to safely 
participate in study procedures and provide interpretable results.  Diagnostic criteria will include 
demonstration of a classic DMD clinical phenotype , increased  serum creatine kinase ( CK), and the 
presence of a mutation in the dystrophin gene consistent with DMD. 
Eligible patients will be ambulatory boys â‰¥4.0 to <8 .0 years of age.  These gender and age criteria are 
intended to facilitate enrollment (as DMD is much more common in boys), and ensure that the 
enrolled patients will be able to complete the timed function tests included in the study as efficacy 
assessments.  In addition, eligible patients must have not used steroids within the 24 weeks  prior to 
initiation of study treatment ( Day 1).  I t is important to evaluate the effects of edasalonexent  in the 
absence of concomitant steroid use since the positive effects of glucocorticoids are thought to be at least partially mediated by their anti-inflammatory  action via modulation of NF -ÎºB, an d 
edasalonexent  is proposed to work through the same pathway (but without the negative side effects).  
While  it is also important to evaluate the efficacy and safety of edas alonexent in the absence of other 
disease-modifying therapies , recent nonclinical data have shown that administration of edasalonexent 
in combination with eteplirsen results in increased dys trophin expression and does not reveal any 
increased risk .  Therefore,  patients who have received at least 24  weeks of treatment with eteplirsen  
prior to Day 1 will be eligible for the study.   
For detailed information on prohibited concomitant medications, please refer to Section  5.3.   
To minimize the risk for practice ef fects  (which could mask potential treatment effects ), decrease the 
heterogeneity of the patient population with respect to disease state, and ensure that patients are not at 
high risk for imminent loss of ambulation, pat ients will be required to  do the following to enroll:  
stand from supine in â‰¤10 seconds, and complete the 10MWT and 4- stair climb . 
It is strongly recommended that all patients receive annual vaccinations for influenza virus. 
Safety Monitoring 
The safety measures used in this study are standard and reflect appropriate monitoring of pediatric 
patients receiving an investigational drug.  Although no adrenal abnormalities have been observed in 
the Phase 1/2 study, CAT-1004-201 (see the Investigatorâ€™s Brochure), s ince weight loss and adverse 
effects on adrenal glands were observed in 13-w eek juvenile rat toxicology studies at plasma 
exposures higher than anticipated in humans, monitoring of adrenal function will be included in this 
study as a precaution .  In addition to monitoring by the Investigators, sub-Investigators and M edical 
Monitors, a DSMB  will provide oversight of the study. 
Efficacy  
The selection of efficacy endpoints was based on consideration of the primary clinical manifestations 
of DMD, namely a progressive loss of muscle strength and the associated impact of this loss on function.  T he potential effects of edasalonexent  on muscle strength and function are assessed by 
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 26 means of  widely used and accepted  measures of  these constructs including NSAA, TFT s, muscle 
strength testing, PUL  entry item assessment , and the PODCI  Transfer and Basic Mobility scale.   
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 27 4. PATIENT POPULATION A ND SELECTION  
4.1. Inclusion Criteria  
A patient must meet all the following criteria to be eligible  for this study. 
1. Written consent/assent by patient and/or legal guardian as per regional and/or Institutional 
Review Board ( IRB)/Independent Ethics Committee ( IEC) requirements  
2. Diagnosis of DMD based on a clinical phenotype with increased serum creatine kinase (CK) 
and documentation of mutation(s) in the dystrophin gene known to be associated with a DMD phenotype  
3. Male sex by birth 
4. Age â‰¥4.0 to <8 .0 years (at the time of consent) 
5. Able to perform stand from supine without assistance in â‰¤10 seconds  
6. Able to perform the 10MWT and 4- stair climb  
7. Able to swallow placebo capsules at the Screening Visit  
8. Followed by a doctor or medical professional who coordinates Duchenne care on a regular basis and willingness to disclose patient's study participation with medical professionals 
4.2. Exclusion Criteria  
A patient who meets any of the following criteria will be excluded from this study. 
1. Use of corticosteroids within 24 weeks prior to Day 1; use of inhaled, intranasal, and topical corticosteroids is permitted  
2. Use of an investigational drug, idebenone, or dystrophin-focused therapy within 4 weeks or a 
period of 5 half-lives duration prior to Day 1 (whichever is longer) or ongoing participation in 
any other therapeutic clinical trial.  Exception: Patients who hav e received at least 24 weeks of 
a stable dose of eteplirsen prior to Day 1, and expected to continue treatment, will be eligible.  
3. Use of the following within 4 weeks prior to Day 1: immunosuppressive therapy, warfarin, phenytoin, S mephenytoin, cyclosporine, dihydroergotamine, ergotamine, fentanyl, alfentanil, pimozide, quinidine, sirolimus, tacrolimus, or paclitaxel 
4. Use of human growth hormone within 3 months prior to Day 1 
5. Documented positive hepatitis B surface antigen, hepatitis C antibody, or human immunodeficiency virus (HIV) or a known risk factor for hepatitis such as a blood transfusion within 12 weeks prior to Day 1 
6. Hemoglobin <10.5 g/dL 
7. Abnormal gamma glutamyl transferase (GGT) (>laboratoryâ€™s upper limit of normal [ULN])  
8. Other prior or ongoing medical condition, known hypersensitivity to omega 3 fatty acids, physical findings, ECG findings, or laboratory abnormality (including but not limited to renal insufficiency or impaired hepatic function) that, in the Investigatorâ€™s opinion, could adversely 
affect the safety of the patient, make it unlikely that the course of treatment or follow up 
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 28 would be completed, or impair the assessment of study results (e.g., a gastrointestinal 
condition that would impair fat absorption) 
9. In the Investigatorâ€™s opinion, unwilling or unable for any reason (e.g., attentional or behavioral issues) to complete all study assessments and laboratory tests and comply with scheduled visits, administration of drug, and all other study procedures 
Note:  Patients may be re -tested or re-screened for eligibility after discussion with the Medical 
Monitor. 
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 29 5. TREATMENTS 
5.1. Treatments Administered  
5.1.1. Double -Blind Placebo -Controlled Treatment  
Eligible patients will be randomly assigned 2:1 to  receive either  edasalonexent 100  mg/kg/day 
(administered as approximately 33 mg/kg TID) or placebo in double- blind fashion daily for 52 weeks .  
The exact capsule count per dose will be provided.  All doses of study drug will be orally 
administered in divided doses with food containing at least 8 grams  of fat.  Nutritional guidance will 
be provided at Baseline.  Patient compliance with the nutritional guidance will be confirmed 
throughout treatment.  The acceptability and palatability of edasalonexent will be explored in this study; data will be collected from patients and caregivers.  
5.1.2. Investigational Product(s) Description  
Description of edasalonexent  capsules: 
â€¢ 100-mg capsules (Size 3 oval) containing 100 mg edasalonexent  formulated with the 
following excipients: polysorbate-80, glyceryl monooleate (type 40), P EG-400, and dl-
alpha-tocopherol , with imprint â€œ####â€ using black iron oxide ink   
â€¢ 250-mg capsules (Size 7.5 oval) containing 250 mg edasalonexent  formulated with the 
following excipients: polysorbate-80, glyceryl monooleate (type 40), PEG -400, and dl-
alpha-tocopherol , with imprint â€œ####â€ using black iron oxide ink   
Description of placebo capsules: 
â€¢ Placebo  100- mg match  capsules (Size 3 oval) containing the following excipients:  
polysorbate-80, glyceryl monooleate (type 40), PEG -400, and dl- alpha-tocopherol, with 
imprint â€œ####â€ using black iron oxide ink 
â€¢ Placebo  250- mg match  capsules (Size 7.5 oval) containing the following excipients:  
polysorbate-80, glyceryl monooleate (type 40), PEG -400, and dl- alpha-tocopherol, with 
imprint â€œ####â€ using black iron oxide ink 
5.1.3. Packaging and Labeling 
The investigational  products described in Section  5.1.2 will be provided to the site  by the Sponsor or 
designee.  Refer to the Study Drug Handling Manual (SDHM)  for additional details .  The Sponsor or 
designee will provide the Investigator with packaged investigational product labeled in accordance with country- specific regulatory requirements.  
5.1.4. Storage 
The investigational products must be stored refrigerated at 2 Â°C to 8Â° C (36Â°F to 46Â°F) at the site .  
Single bottles dispensed to patients may be stored at up to 25Â° C (77Â°F; controlled room temperature) 
for up to 30 days.  Refer to the SDHM for additional details.  
5.1.5. Preparation and Adm
 inistration 
Refer to the SDHM for additional details .   
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 30 5.2. Dosing Considerations  
5.2.1. Dose Selection Rationale 
See Section  2.3 for details  on dose rationale. 
5.2.2. Dose Modification or Reduction  
Temporary or persistent dose reductions may be made for safety or tolerability  at any time during the 
study.  Refer to Section  7.9 for additional details.  
5.2.3. Safety Monitoring 
Safety will be monitored on an ongoing basis by the Investigator, Medical Monitor, and Sponsor.  In 
addition, the DSMB will review relevant study data (as defined in the DSMB charter)  to decide on 
the continuation, termination, or modification of the trial (also see Section  8.4).   
5.2.4. Treatment Compliance  
Throughout the study, patients and their parents/ caregivers  will complete  a diary documenting 
investigational product administration , and  diet compliance.  Upon completion of data entry, the 
database will undergo a quality review to ensure acceptable accuracy and completeness .  In addition, 
site call s, which will occur throughout the study as noted in the SOA ( Appendix 1) , will include a 
compliance check on  investigational product administration and diet.  Detailed information regarding 
the study- specific dietary requirements and the process for monitoring compliance to the diet are 
provided in the Study Reference Manual (SRM). 
5.2.5. Treatment Discontinuation  
A patientâ€™s study treatme nt may be discontinued at any time at the patientâ€™s/ parent/legal guardian â€™s 
request or at the discretion of the Investigator, Medical Monitor or Sponsor.  The following may be 
justifiable reasons for the Investigator , Medical Monitor or Sponsor to discontinue a patient from 
treatment: 
â€¢ The patient experiences an  intolerable or unacceptable AE 
â€¢ The patient is unable to comply with the requirements of the protocol 
â€¢ The patient participates in another investigational study without the writt en authorization 
of the Sponsor 
Discontinuation of treatment does not imply withdrawal from the study.   
Patients who discontinue treatment prematurely will be asked to  complete the early termination visit 
prior to their last dose of study drug as noted in the SOA in  Appendix 1.   
5.3. Prior and Concomitant Medications and Therapeutic Procedures  
In general, disease -modifying drugs, investigational drugs, immunosuppressive therapy, and  drugs 
with narrow therapeutic indices metabolized by CYP3A4, CYP2C8, CYP2C9, and CYP2C19 are 
prohibited for at least 4 weeks prior to Day 1 and during the study ( Table 2) .  Recent nonclinical data 
have shown that administration of edasalonexent in combination with eteplirsen  results in increased 
dystrophin expression and does not reveal any increased risk.  In regions where eteplirsen is approved 
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 31 or there is an established access program , patients who have received at least 24  weeks of treatment 
with eteplirsen prior to Day 1 will be eligible for the study.   
Throughout the study, Investigators may prescribe c oncomitant medications or treatments deemed 
necessary to provide adequate supportive care to patients .   
Treatment with corticosteroids is prohibited within 24 weeks prior to Day  1 and during the study 
(Table 2).   
All medications should be taken as prescribed, per Investigator judgment, even when blood samples 
are planned to be drawn .  In addition, all concomitant medications, including supplements must be 
recorded in the source documentation and in the eCRF.   
Note:  Annual vaccination for influenza is strongly recommended for all patients. Table 2: Prohibited Prior and Concomitant Medications  
Medication  Prohi bited within 
24 weeks prior to  Day 1  Prohibited within 
4 weeks  prior to  Day 1a Initiation prohibited 
throughout the study  
Corticosteroids b X X X 
Deflazacort ( Emflazaâ„¢) X X X 
Ataluren ( Translarnaâ„¢)  X X 
Idebenone ( RaxoneÂ®)  X X 
Other investigational drugs   X X 
Immunosuppressive therapy   X X 
Warfarin, phenytoin, 
S mephenytoin, cyclosporine, 
dihydroergotamine, ergotamine, fentanyl, alfentanil, pimozide, quinidine, sirolimus, tacrolimus , 
paclitaxel   X X 
 Eteplirsen ( Exondys 51â„¢) c   X 
a If 5 half -lives of the drug is >4 weeks, drug is prohibited for 5 half -lives prior to Day 1.  
b       Use of inhaled, intranasal, and topical corticosteroids is permitted.  
c       Use of eteplirsen is permitted if on a stable dose for at least 24 weeks prior to Day 1.  
5.4. Method of Assigning Patients to Treatment  
During the study, patients will be randomly assigned  in a 2:1 ratio to receive edasalonexent  or 
placebo  in double-blind fashion.   
5.5. Blinding and Randomization  
5.5.1. Blinding and Randomization 
Approximately 126 patients will be randomized 2:1 to receive edasalonexent or placebo in double-
blind fashion daily for 52 weeks .  Randomization will be stratified by Baseline age (â‰¤6.0 years or 
>6.0 years), time to stand from supine (â‰¤5 seconds or >5 secon ds), treatment with eteplirsen  (yes or 
no), and region (North America or Europe/ Asia/Australia ). 
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 32 If siblings are enrolled, only one sibling will be included in the Randomized Population, the second 
sibling  will be assigned  to the same treatment group as th e randomized sibling (see Section  9.3).  If 
both siblings meet the inclusion/exclusion criteria, the sibling to be included in the Randomized 
Population will be the first sibling randomized . 
5.5.2. Scheduled Unblinding  
After completion of the study, patients, monitors, Investigators, study center personnel, and the 
Sponsor will remain blinded to treatment assignments until results from the  study are available.   
5.5.3. Emergency Unblinding  
Prior to scheduled unblinding (see  Section  5.5.2), if an emergency where the identity of the 
investigational product must be known by the Investigator to provide appropriate medical treatment occurs , the Investigator will be allowed to unblind using the Inte ractive Web Response System 
(IWRS).  Before doing this , the Investigator should make every effort to discuss the situation with the 
Medical Monitor. 
The treatment assignment should only be unblinded when knowledge of the treatment assignment 
will impact the clinical management of the patient.  Every reasonable attempt should be made to 
complete the final treatment assessment procedures prior to unblinding, as knowledge of the 
treatment assignment c ould influence patient assessment .   
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 33 6. STUDY  ASSESSMENTS  
6.1. Study Schedule of Events  
The SOA for the study is provided in Appendix 1. 
The modified SOA for this study during the COVID-19 pandemic is provided in Appendix 2. 
6.2. Screening and Baseline Assessments  and Start of Treatment  
Once written informed  consent, and when appropriate, written assent  is obtained, patient s will be 
screened for  eligibility for entry into the study based on the inclusion and exclusion criteria  detailed 
in Sections  4.1 and  4.2.  A full medical/surgical history will be obtained, including information 
relating to any prior or existing medical conditions/surgical procedures that  may be relevant to the 
patientâ€™s experience in the study .  Demographic data and DMD- specific medical history information 
will also be recorded .  Patients will undergo a full physical examination , including vital signs ( see 
Section s 6.4.1 and  6.4.2) , safety labs, a 12-lead ECG tracing will be obtained , and body weight wi ll 
be measured .  Additional cardiac monitoring will be performed via a wearable cardiac monitoring 
device to measure heart rate and heart rate variability if approved for use in the country.  T he 
laboratory assessments  shown in Appendix 3 will be performed .   
Screening assessments should be completed within 4 weeks  of Day 1. 
At Baseline, patient eligibility for the study will be reconfirmed and the patient will be randomized .  
Patients will undergo a full physical examination .  Height and body weight will be measured and 
body mass index (BMI) will be calculated.  Any AEs or changes in concomitant medications since 
Screening will be recorded .  Patients will undergo Baseline efficacy evaluations as specified in  
Appendix 1, and blood samples will be drawn for safety, ACTH/cortisol, biomarkers and gene expression.  Bone evaluations (spine radiography and DXA scan) will be performed  if approved by 
the appropriate governing bodies at each site or country.  Patients and their families will be provided 
with written and verbal instructions for study drug administration.  Nutritional guidance will also be 
given and study drug will be dispens ed. 
6.3. Efficacy Assessments 
Efficacy  will be assessed at the timepoints specified in  Appendix 1.  
6.3.1. North Star Ambulatory Assessment (NSAA) 
The NSAA is a clinician -reported outcome instrument designed to measure ambulatory function in 
males with DMD (Scott, 2012) .  During this assessment, patients are asked to perform 17 different 
functional activities, including a 10MWT, rising from supine, rising from a sit to stand, standing on 1 leg, e.g., climbing and descending a step, rising from the floor, lifting the head, standing on heels, 
and jumping.  The NSAA has undergone detailed psychometric evaluations based on traditional 
(reliability and validity ) and modern (Rasch analysis) methods, and  has been included in international 
clinical trials (Kinali, 2009) .  In addition, 36- month longitudinal data are available in patients with 
DMD ( Mazzone, 2011; Pane, 2014b) .  The NSAA will be administered by trained evaluators; every 
effort will be made to have the same evaluator perform all assessments for a given child at the same time of day.  Completion of this test is expected to take approximately 20- 30 minutes.  
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 34 Additional details on the performance of the NSAA are provided in the Clinical Evaluator  Manual.  
6.3.2. Timed  Function Testing  
TFTs will include the 10MWT  and the stand from supine (as measured in  the NSAA)  as well as the  
4-stair climb .  These test s have been used as clinical trial endpoints in DMD and have shown 
response to therapeutic intervention with steroids ( Mendell, 1989; Griggs, 1990; Beenakker, 2005; 
Manzur, 2009) .  TFTs will be performed by trained evaluators ; every effort will be made to have the 
same evaluator  perform all assessments for a given child  at the same time of day .  Completion of 
TFTs is expected to take approximately 10 minutes.  
Additional details on the performance of the TFTs is provided in the Clinical Evaluator  Manual.  
6.3.3. Muscle Strength Testing  
Muscle strength testing will include assessment of knee extension and elbow flexion.  Muscle testing  
will be performed using a hand-held dynamometer.  Knee myometry will be performed while the  
patient is in a  sitting position .  Elbow myometry will be performed while th e patient is positioned 
supine.  Muscle testing will be performed by trained evaluator s; every effort will be made to have the 
same evaluator  perform all assessments for a given child  at the same time of day .  Completion of each 
muscle test is expected to take approximately 10-15 minutes , for a total of 20-30 minutes .   
Additio nal details on the assessment of muscle strength  are provided in the Clinical Evaluator  
Manual.  
6.3.4. Performance of Upper Limb  (PUL) Scale 
The PUL was specifically designed by an international Clinical Outcomes Group consisting of 
clinicians, scientists, patient advocacy groups and industries representative to assess upper limb function in ambulant and non-ambulant DMD patients ( Mercuri, 2012; Mayhew, 2013b) .  The PUL is 
made up of a 6-point entry item (based on the modified Brooke Upper Extremity Scale) to define the starting functional level, and 22 items subdivided into shoulder level (6 items), middle level (9 items) and distal level ( 7 items) dimension (Pane, 2018) .  Loss of full overhead reach occurs at median age 
9.6 with some boys losing the ability as early as age 5 or 6 ( McDonald, 2018) .  Patients will perform 
the PUL entry item assessment as specified in  Appendix 1.  Based on the age of patients in this study, 
most patients will score a 6 on the 6 -point entry item assessment.  Those patients  who score a 6 on the 
6-point entry item assessment will no t be required to perform the additional items.  Patients who 
score below a 6 on the 6-point entr y item assessment will perform a subset of the PUL battery 
including the shoulder level dimension and supination, consisting of 7 items with a maximum score 
of 14.  In boys with DMD, the PUL has robust internal reliability, validity, and hierarchical 
scalability (Mayhew, 2013a ), excellent interobserver and intra- observer reliability (Pane, 2014a ), and 
is sensitive to changes over time (Seferian, 2015)  and in response to steroid treat ment (Pane, 2015 ).  
It may be most suitable for DMD patients 5 years of age and above.  Completion of the 6-point entry 
item assessment is expected to take approximately 5 minutes. Completion of the battery of PUL 
assessments is expected to take approximately 20 minutes.  
Additional details on the PUL scale are provided in the Clinical Evaluator Manual . 
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 35 6.3.5. The Pediatric Outcomes Data Collection Instrument (PODCI ) 
The PODCI  is a well -validated tool for assessment of health -related functioning in children, and  has 
been used in a study of boys with DMD (Henricson, 2013) .  It is designed to be completed by the 
parent/caregiver  of children aged 10 or younger, contains 86 questions, takes approximately 
20-30 minutes to complete , and provides information on the following 6 scales:  
â€¢ Upper Extremity and Physical Function Scale:  Measures difficulty encountered in 
performing daily personal care and student activitie s. 
â€¢ Transfer and Basic Mobility Scale:   Measures difficulty experienced in performing routine 
motion and motor activities in daily activities.  
â€¢ Sports and Physical Functioning Scale:  Measures difficulty or limitations encountered in participating in more active activities or sports .   
â€¢ Pain/Comfort Scale:  Measures the level of pain experienced during the past week. 
â€¢ Happiness Scale:  Measures overall satisfaction with personal looks and sense of 
similarity to friends and others of own age. 
â€¢ Global Functioning Scale:  A general combined s cale calculated from the first 4 scales 
listed above. 
Parents/caregivers will complete the PODCI listed in  Appendix 5 at timepoints listed in  Appendix 1. 
6.3.6. Assessor Training and Ensuring Compliance with Protocol -Specified Test -
Administration.  
The following efficacy assessments will be administered by trained evaluator s:  NSAA, TFTs, muscle 
strength testing , and PUL.  To help ensure proper and consistent test administration across 
evaluator s/sites, all evaluator s will undergo training on the proper administration of the se assessments 
prior to the study.  As part of this training, therapists will administer each assessment to boys with DMD who are not participating in the study; test administrations will be videotaped, reviewed for adherence and inter -rater consistency, and feedback will be provided as applicable. 
To help ensure proper and consistent test administration over the course of the study, administration of NSAA, TFT s, and muscle strength testing may be videotaped and reviewed for each patient at 
Screening  and Week 52 and may also  be required at  Baseline as specified in  Appendix 1. 
Additional information on the training and monitoring of the administration of these tests is provided in the Clinical Evaluator  Manual.   
6.4. Safety Assessments  
Safety will be assessed for all enrolled patients from Screening through the  safety follow-up, as 
specified in  Appendix 1.  Safety parameters  include physical examinations, growth parameters , vital 
signs, clinical laboratory tests  (including chemistry, hematology, urinalysis, and tests for adrenal 
function), ECGs, and concomitant medication monitoring as described in Section  6.4.5 and AEs as 
described in Section  7.  A list of all required clinical laborator y assessments is provided in 
Appendix 3.   
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 36 6.4.1. Physical Examination and Growth Parameters  
The physical examination s will include an assessment of the patientâ€™s general appearance; skin; head, 
ears, eyes , nose, throat ( HEENT ); lymph nodes; heart; lungs; abdomen; extremities/joints; and 
neurological and mental status.  Physical examinations should be performed by the same person when 
possible.  Height and weight will be measured a t the timepoints  specified  in Appendix 1 and BMI 
will be calculated.  
6.4.2. Vital Signs  
Vital s igns (blood pressure, heart rate, respiratory rate, and temperature) will be measured at the 
timepoints specified in  Appendix 1.  Systolic and diastolic blood pressure ( preferably assessed on the 
same arm each time) will  be measured only after the patient is positioned in a semi -supine position 
and resting for at leas t 5 minutes .   
6.4.3. Clinical Laboratory Tests 
Blood and urine samples will be collected for clinical laboratory evaluations (see Appendix 3 for a 
complete l ist of analytes ). 
The clinical laboratory tests to be done at Screening  include hematology with differential, chemistry,  
and urinalysis.   
Blood samples for ACTH and cortisol will be obtained at Baseline before initiation of treatment.   
Chemistry, hematology, and ACTH/cortisol assessments done during the treatment period  will be 
performed in the morning when possible.   
A central laboratory will provide collection supplies, arrange collection, and perform analysis of 
clinical laboratory e valuations indicated in Appendix 3.  Using the central laboratory for unscheduled 
clinical laboratory evaluations and re peat testing  is recommended .  Procedures for the handling and 
shipment of all central laboratory samples will be included in the Laboratory Manual.  Specimens will be appropriately processed by the central laboratory facility and laboratory reports will be made available to the Investigator in a timely manner to ensure appropriate clinical review.  
The enrolling Investigator is responsible for reviewing and signing all laboratory reports unless the 
patient is transferred to another site for all subsequent visits .  The clinical significanc e of each value 
outside of reference range will be assessed by the Investigator and documented as either not clinically 
significant (NCS ) or clinically significant.  All clinically significant values require a comment and the 
out-of-range value or the overlying diagnosis (or value if the diagnosis is unknown) must be captured as an AE.  
Clinical laboratory reports will serve as source documents. 
6.4.4. Electrocardiogram  
The 12-lead ECG s will be performed only after the patient is positioned supine, resting, and quiet for 
a minimum of 5 minutes .  If findings are abnormal, the Investigator is responsible for indicat ing 
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 37 whether the ECG tracing is NCS or clinically significant.  In addition, E CGs will be  centrally 
evaluated .   
6.4.5. Concomitant Medications and Therapies  
Concomitant medications  and therapies  are to be assessed at all visits .  Reasonable efforts will be 
made to determine all treatments (pharmacological and non-pharmacological) received by the patient .   
A medication/therapy is considered concomitant if it is taken/administered  at any time from 
Screening  through the final study evaluation. 
Data on pharmacological and non- pharmacological treatments will be recorded on an  eCRF page, to 
include:  drug name/name of procedure, dose, route, regimen, start date, stop date, and indication.  At 
each study visit, the parent or caregiver  will be asked about any additional treatments or any changes 
in regimen or dosages since the last visit.  Indications for any new medications or therapies during the study period will be recorded as an AE.  
Patients and their parents/caregivers will be contacted by the site  between scheduled visits to assess 
concomitant medications and AEs (as indicated in  Appendix 1).  
For detailed information on prohibited concomitant medications please refer to  Section  5.3.   
6.5. Pharmacokinetic Assessments  
Samples for determination of edasalonexent and its metabolite  concentration s will be drawn at 
selected visits as detailed in  Appendix 1.  
In addition to the PK analyses described, any of the collected PK plasma and urine sa mples from 
study patients may also be used for profiling of drug binding proteins, bioanalytical method 
validation purposes, stability assessments, metabolite assessments, or to assess other actions of study 
drug with plasma constituents. 
6.6. Pharmacodynamic  Assessments  
Blood samples will be obtained at selected visits as indicated in  Appendix 1.  Assessments may 
include: 
â€¢ Circulating protein biomarkers to evaluate course of disease and /or response to treatment  
â€¢ DNA, RNA (ribonucleic acid) , and micro- RNA samples may be collected and used for 
pharmacogenomic analys es that might predict the course of disease and/or responses to 
treatment  as well as analysis of drug metabolizing enzyme and/or transporte rs. 
Details of blood collection procedures will be provided in the Laboratory Manual.   
6.7. Cardiac Monitoring  
Patients with DMD are known to have resting tachycardia even in the age range in this clinical study 
(Thomas, 2012) .  Additionally, decreases in heart rate variability have been observed ( Thomas, 
2015) .  Since decreases in heart rate to age -normative values were observed in a previous clinical 
study (CAT-1004- 201), measures of heart rate and variability will be colle cted for approximately 48 
hours via a wearable cardiac monitoring device if approved for use in the participating country. In 
addition, the results from the patientâ€™s last cardiac assessment should be documented as part of 
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 38 medical history. Prospective cardiac assessments performed should also be documented as part of 
ongoing procedures. 
6.8. Bone Evaluations  
Patients with DMD have a deficiency of bone mineral density and increase d incidence of bone 
fractures  which becomes more severe when taking corticosteroids .  Patients who use corticosteroids 
have over two times as many fractures as steroid naÃ¯ve patients  (King, 2007 ).  Fractures that occur in 
lower extremities can lead to early loss of ambulation.  Bone evaluations will be performed  through 
lateral thoracolumbar spine radiography and DXA scan.  In Germany, bone assessment will not be 
performed until the respective approvals from the German Federal Office for Radiation Protection (Bundesamt fÃ¼r Strahlenschutz ) become available.  A qualified medical professional will review the 
results of the lateral thoracolumbar spine radiography and DXA scan and designate the findings as 
normal or abnormal; if abnormal, the Investigator will indicate whether the scans are NCS or clinically significant.  In addition, bone radiography will be centrally evaluated.  
6.9. Study Drug Acceptability  
To evaluate the acceptability and pal atability of edasalonexent, caregivers will complete the study 
drug questionnaire listed in  Appendix 4  at timepoints  indicated in Appendix 1.  
6.10. Total Volume of Blood Collected  
The total n umber of venipunctures and the total volume of blood collected during the study will be 
limited to that needed for safety monitoring, PK, and PD  measurement .  Refer to the SRM  and/or 
laboratory manual for the collection preparation and procedures as well as the estimated  total volume 
of blood to be collected during the study.  The total blood volume collected from each patient for the 
entire  study is within the guidelines set forth by the World Health Organization ( WHO ) (Howie,  
2011) . 
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 39 7. ADVERSE EVENT S AND ADVERSE EVENT  REPORTING 
At each study visit, patients will be evaluated for new AEs and the status of existing AEs.  The 
Investigator may elicit symptoms using an open-ended question, followed by appropriate questions 
that clarify the patientâ€™s verbatim description of AEs or change in concomitant medications.  T he 
enrolling Investigator is responsible for safety oversight of data for all visits  unless the patient is 
transferred to another site for all subsequent visits.  All AEs from the time of signing the informed 
consent through follow-up will be recorded on the eCRF.  
7.1. Timeframe for Collection of Adverse Events 
7.1.1. Adverse Events Occurring Prior to Study Treatment  
All AEs that occur between the time informed consent is provided and the patientâ€™s receipt of the first dose of investigational product will be considered pretreatment AEs. 
7.1.2. Adverse Events Occurring After Study Treatment  
All AEs that occur from the time of the administration of the first dose of investigational product 
through the end of the safety f ollow-up will be considered treatment- emergent AEs  (TEAEs) .  
7.1.3. Adverse Events Occurring Following Patient Discontinuation of Treatment 
For patients who prematurely discontinue study treatment ( see Section  5.2.5), but who are not 
withdrawn from the study, AEs will continue to be recorded until the patient completes the study ( see 
Section  3.3.3.1 for definition of patient completion).  See Section  7.6 for reporting requirements after 
the patient completes the study. 
7.2. Definitions  
7.2.1. Definition of an Adverse Event  
An AE is any untoward medical occurrence in a clinical investigation patient, which does not 
necessarily have a causal relationship with the investigational product (active or placebo drug, biologic, or device).  An AE can, therefore, be any unfavorable and unintended symptom, sign, disease or condition, or test abnormality, whether  considered related to the investigational product. 
Adverse events include: 
â€¢ Symptoms described by the patient or signs observed by the Investigator or medical staff  
â€¢ Test abnormalities (laboratory tests, ECG, X- rays, etc. ) that result in an alteration in 
medical c are (diagnostic or therapeutic) 
Adverse events do not include: 
â€¢ Changes that are characteristic of disease progression in Duchenne  
Abnormalities present at Baseline are considered AEs only if they reoccur after resolution or they worsen during the study. 
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 40 7.2.2. Definition of a Serious Adverse Event  
Seriousness of an AE serves as a guide for defining regulatory reporting obligations.  An SAE is any 
AE that results in any of the following: 
Death :  The patient died as the result of the event. 
Life-threatening event :  Any AE that places the patient, in the view of the Investigator, at immediate 
risk of death from the AE as it occurred, i.e., does not include an AE that had it occurred in a more 
severe form, might have caused death. 
Required or prolonged inpatient hospitalization:  The AE resulted in an initial inpatient 
hospitalization or prolonged an existing hospitalization of the patient.  Note:  Planned hospital admissions, or surgical procedures for an illness or disease that existed before the a dministration of 
the study treatment or before the patient was enrolled in the study, will not be captured as SAEs unless they occur at a time other than the planned date. 
Persistent or significant disability/incapacity:  An AE that results in a substantial disruption of a 
personâ€™s ability to conduct normal life functions. 
Congenital anomaly/birth defect:  A congenital anomaly/birth defect that occurs in the offspring of a 
patient exposed to the investigational product. 
Important medical events :  An AE that may not result in death, be life-threatening, or require 
hospitalization may be considered an SAE when, based upon appropriate medical judgment, the event may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed above. 
7.3. Evaluation of Adverse Events/Serious Adverse Events  
7.3.1. Relationship to Study Treatment  
Assessment of the association between the AE and study drug exposure is important for regulatory reporting.  For each AE/SAE , the Investigator will  determine whether there is a reasonable possibility 
that the AE may have been caused by the study drug according to the following categories:  
Not Related :  The AE is clearly not related to study drug. 
Unlikely Related :  There is no evidence of a causal relationship between study drug and the AE; 
although such relationship cannot be ruled out. 
Possibly Related :  There is some evidence supporting the possibility of a causal relationship between 
study drug and the AE. 
Related :  There is stron g evidence that there is a causal relationship between study drug and the AE. 
A relationship to the investigational product must be given for each AE/SAE recorded, even if there is only limited information at the time .  The Investigator may change his/her opinion of causality in 
light of follow-up information, amending the AE/SAE report accordingly. 
7.3.2. Severity Grading of Adverse Event Scoring  
Note that severity  is not the same as â€œseriousness,â€ which is defined in Section  7.2.2.   
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 41 The Investigator will grade the severity of all AEs/SAEs as mild, moderate, or s evere, based on the 
following definitions ( developed from Clinical Data Interchange Standards Consortium [CDISC] 
Study Data Tabulation Model [SDTM] standard terminology v3.1.1): 
Mild:  A n AE  that is usually transient and may require only minimal treatment or therapeutic 
intervention.  The event does not generally interfere with usual acti vities of daily living.  
Moderate:  A n AE that is usually alleviated with specific therapeutic intervention .  The event 
interferes with usual activities of daily living, causing discomfort, but poses no significant or 
permanent risk of harm to the research participant.  
Severe:  A n AE that interrupts usual activities of daily living, or significantly affects clinical status, or 
may require intensive therapeutic intervention. 
7.3.3. Outcome 
Outc ome describes the status of the AE.  The Investigator will provide information regarding the 
patient outcome of each AE. 
Possible results of an AE outcome are defined as follows : 
Fatal :  The termination of life as a result of an AE.  
Not recovered/not resolved:  The patient has not recuperated or the AE has not improved. 
Recover ing/resolving:  The patient is recuperating or the AE is improving. 
Recovered/resolved:  The patient has recuperated or the AE has resolved.  
Recovered with sequelae/resolved with sequelae:  The AE has resolved, but the patient has been left 
with symptoms o r pathology. 
Unknown:  Not known, not observed, not recorded, or refused. 
7.3.4. Action Taken Regarding the Investigational Product 
The Investigator will be required to provide the action taken regarding investigational product (e.g., 
active, comparator ) in response to the AE according to the following categories: 
Dose not changed:  No change in administration of the investigational product. 
Dose reduced :  Reduction in the frequency, strength or amount of investigational product 
administered.  
Drug (investigational product) interrupted:  Temporary interruption ( termination ) in administration of 
the investigational product. 
Drug (investigational product) withdrawn :  Administration of the investigational product terminated 
(no further dosing). 
Not applicable:  Determination of a value is not relevant in the current context. 
Unknown:  Not known, not observed, not recorded, or refused. 
&OLQLFDO7ULDO3URWRFR O&$7 $SULO
&RQILGHQWLDODQG3URSULHWDU\ 5HFRUGLQJRI$GYHUVH(YHQWV6HULRXV$GYHUVH(YHQWV
$OO$(V6$(VH[SHULHQFHGE\WKH SDWLHQWZLOOEHUHFRUGHGRQWKH H&5)7KHIROOR ZLQJLQIRUPDWLRQ
ZLOOEHUHFRUGHGDFRQFLVHGHV FULSWLRQRIWKHH YHQWGDWHDQG WLPHRIHYHQWRQVHW DQGUHVROXWLRQ
GHWHUPLQDWLRQRIVHULRXVQHVVV HYHULW\FRUUHFWLYHWUHDWPHQWR XWFRPHDQGUHODWLRQVKLSWR
LQYHVWLJDWLRQDOSURGXF WDQGDFWLRQWDNHQUHJDUGLQJWKHLQYHVW LJDWLRQDOSURGXFW $EQRUPDOYLWDO
VLJQVODERUDWRU\UHVXOWVRURW KHUDEQRUPDOVDIHW\DVVHVVPHQWV QRWHGLQ6HFWLRQ ZLOOEHUHFRUGHG
DVDQ$(LIWKH\PHHWWKH GHILQLWLRQRIDQ$(VHH 6HFWLRQ :KHQSRVVLEOHD GLDJQRVLVVKRXOGEH
UHFRUGHGDVDQ$(UDWKHUWKDQV \PSWRPVRULVRODWHGODERUDWRU\D EQRUPDOLWLHVUHODWHGW RWKDWGLDJQRVLV
$PHGLFDORUVXUJLFDOSURFHGXUH LVQRWDQ$(UDWKHUWKHFRQGLW LRQOHDGLQJWRWKHSURFHGXUHVKRXOGEH
UHFRUGHGDVWKH$(,IWKHFRQGLWLRQLVQRWNQRZQWKHSURFHGX UHPXVWEHUHSRUWHGD VDQ$(LQVWHDG
6LPLODUO\GHDWKLVQRWDQ$(EXWU DWKHULVWKHRXWFRPHRIWKH $(VWKDWUHVXOWHGLQGHDWK,IWKH
$(VOHDGLQJWRGHDWKDUHQRWNQRZ QWKHQGHDWKPXVWEHUHSRUW HGDVDQ$(
$OO6$(VH[SHULHQFHGE\WKHSD WLHQWZLOOEHUHFRUGHGRQWKH$( H&5)DQGUHSRUWH GWRWKH6SRQVRURU
LWVGHVLJQHHDFFRUGLQJWR 6HFWLRQ 
&29,'$GYHUVH(YHQWVDQGRU6HULRXV$GYHUVH(YHQWV
)RUDQ\VWXG\SDUWLFLSDQWVH[KLE LWLQJV\PSWRPVFRQVLVWHQWZLWK &29,'WKHVHQHHGWREHFDSWXUHG
DVDGYHUVHHYHQWVRUVHULRXVD GYHUVHHYHQWVDFFRUGLQJWRWKHHV WDEOLVKHGVDIHW\U HSRUWLQJV\VWHP
VSHFLILHGLQWKHVWXG\SURWRFRO, QWKHHYHQWDSDUWLFLSDQWWHV WVSRVLWLYHIRU&29,'RULIQRWHVWLQJ
LVDYDLODEOHHQVXUHDSSURSULDW HGRFXPHQWDWLRQRI WKH$(DQGRU 6$(RI&29,'LV UHIOHFWHGLQWKH
H&5)DQGWKHVWXG\VSHFLILF6$(UHSRUWIRUP
5HSRUWLQJRI6HULRXV$GYHUVH(YHQWV
$OO6$(VRFFXUULQJIURPWKHWLPH RILQIRUPHGFRQVHQWXQWLOG D\VIROORZLQJWKHODVWDGPLQLVWUDWLRQ
RIVWXG\GUXJPXVWEHUHSRUWH GZLWKLQKRXUVRIWKHNQRZOHGJH RIWKHRFFXUUHQFHWKLVUHIHUVWRDQ\
$(WKDWPHHWVDQ\RIWKHDIRUH PHQWLRQHGVHULRXVFULWHULDLQ 6HFWLRQ 6$(VWKDWWKH,QYHVWLJDWRU
FRQVLGHUVUHODWHGWRVWXG\GUXJWKD WRFFXUDIWHUWKH'D\IRO ORZXSSHULRGPXVWD OVREHUHSRUWHG
$OO6$(VVKRXOGEHUHSRUWHG LPPHGLDWHO\ZLWKLQKRXUVRIVLWH DZDUHQHVVRIWKHHYHQW7KH
,QYHVWLJDWRUVKRXOGFRPSOHWHWKH SDSHUVWXG\6$(UHSRUWIRUPDQ GVHQGWKHLQLWLDO6$ (UHSRUWZLWKLQ
KRXUVWR39GHSDUWPHQWYLDHPD LOID[DVSHUFRQWDFWGHWDLOV EHORZ

6DIHW\&RQWDFW,QIRUPDWLRQ
(PDLO 
2IILFH 'LUHFW 

0RELOH )D[ 
7KH,QYHVWLJDWRULVUHTXLUHGWRVXEPLW6$(UHSRUWVWRWKH,5%R U,(&LQDFFRUGDQFHZLWKORFDO
UHTXLUHPHQWV$OO,QYHVWLJDWRU VLQYROYHGLQWULDOVXVLQJWKHV DPHLQYHVWLJDWLRQDO SURGXFWZLOOUHFHLYHPI
PI
PI
PI
PIP
I
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 43 any safety alert notifications for onward submission to their local IRB/IEC as required.  All reports 
sent to Investigators will be blinded. 
The Investigator must continue to follow the patient until the SAE has resolved  or until the condition 
becomes chronic in nature, stabilizes (in the case of persistent impairment) or the patient dies.  Within 
24 hours of receipt of follow-up information, the Investigator must update the SAE form 
electronically in the EDC system for the study and submit any supporting documentation (e.g., patient discharge summary or autopsy reports) to contacts above via fax or e- mail.  If it is not possibl e to 
access the EDC system, refer to the procedures outlined above for initial reporting of SAEs.   
7.7. Follow-up of Adverse Events/Serious Adverse Events  
All AEs/SAEs documented at a previous visit/contact that are designated as not recovered/not resolved or recovering/resolving will be reviewed by the Investigator at subsequent visits/contacts. 
All AEs will be followed until the parameter returns to its Baseline status , resolution of AE, 
completion of the patientâ€™s participation, agreement is reached between the Investigator and Sponsor 
that the even t no longer requires follow-up, or study termination, whichever occurs first.  S AEs will 
be followed until resolution, the condition stabilizes, or the Investigator and Medical Monitor agree 
that follow -up is no longer necessary .  Rules for AE/SAE follow -up apply to all patients, including 
those withdrawn prematurely to the extent allowed by the patientâ€™s consent .  The Investigator will 
ensure that follow-up includes further investigations consistent with appropriat e medical management 
and patient consent to elucidate the nature and/or causality of the AE/SAE. 
7.8. Pregnancy Reporting  
Not applicable for this study. 
7.9. Temporary or Persistent Dose Reductions  
Temporary or persistent dose reductions may be made for safety or tolerability reasons in the 
judgment of the Principal Investigator.  If at any time after initiation of treatment the patient 
experiences a clinically significant AE indicative of drug intol erance, the patient will undergo clinical 
assessment as soon as reasonably possible.  The Principal Investigator should discuss any potential 
dose modifications or reduction  with the Medical Monitor .   
7.10. Monitoring of Abnormal Laboratory Values  
Elevations in alanine aminotransferase (ALT ) and aspart ate aminotransferase ( AST ) are common in 
patients with DMD, so exclusion of patients with abnormal Baseline values is not feasible .  Patients 
with abnormal GGT will be excluded.   
During the study, liver function tests will be monitored, including ALT, AST, GGT, alkaline 
phosphatase, glutamate dehydrogenase, and bilirubin.  If increases in ALT or AST are noted, the 
relationship of these to CK will be determined, as well as to GGT and measures of liver synthetic 
function.  Trends in these parameters will be monitored .  Safety alert flags for the Investigator and 
Medical Monitor will include an alert for increases in ALT >150  U/L with stable or decreased CK,  as 
well as for  total bilirubin , glutamate dehydrogenase, or GGT parameters greater than the ULN.   
Additional information on s afety alert flags will be included in the Laboratory Manual.   
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 44 7.11. Stopping Rules  
Either the Investigator or Medical Monitor may stop dosing in individual patients based on 
tolerability  or AE s. 
7.12. Restriction on the Lifestyle of Patients  
Not applicable.  
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 45 8. DATA COLLECTION, QUA LITY ASSURANCE, AND 
MANAGEMENT  
8.1. Recording of Data  
The Investigator must provide the Sponsor or its designee direct access to each patientâ€™s source 
docum ents.  Source documents may include, but are not limited to, the following original documents, 
data, and records where information is  first recorded.  
â€¢ Hospital records 
â€¢ Medical histories and narrative statements relating to the patientâ€™s progress  
â€¢ Clinical an d office charts (electronic or paper ) 
â€¢ Operative reports  
â€¢ Laboratory notes/reports 
â€¢ Project -specific worksheets (e.g., for study visits), including all worksheets developed 
specifically for this study  
â€¢ X-ray, MRI, and computed tomography ( CT) reports  
â€¢ Cardiac ultrasound, echocardiogram  
Required data for this study will be captured using eCRFs via EDC  unless other wise specified in this 
document, below. 
Clinical data that are not recorded on the eCRF will be captured and transferred to the Sponsor or its 
designee.  
8.2. Data Quality Assurance  
The eCRFs will be reviewed by the Sponsorâ€™s clinical monitor or designee for completeness and accuracy .  Source document verification will be performed.  The data will also be reviewed internally 
by the Sponsorâ€™s Data Management department or its designee and, if necessary, the investigational sites will be queried for corrections and/or clarifications.  Upon completion of data entry and reconciliation, all EDC user access privileges will be changed to read only .  Upon completion of data 
entry, the database will undergo a quality review to ensure acceptable accuracy and completeness .   
8.3. Data Management  
The format and content of the eCRF will be approved by the Sponsor or its designee prior to the start of the study.  The Sponsor or its designee will be responsible for database creation, data entry if 
applicable, and management of data from sources other than the clinical database (e.g., laboratory 
data).  Once all patients have completed all study visits , the database will be cleaned, locked , 
unblinded and the statistical analysis will be performed . 
8.4. Data Safety Monitoring Board  
External oversight for this trial will be provided by a DSMB, which will include physicians experienced in treating DMD  and a biostatistician ex perienced in clinical trials .  The  primary 
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 46 responsibility of the DSMB  is to protect the safety and welfare of patients  participating in this  clinical 
trial and to ensure the integrity of the clinical trial.   
Specifically, for this study, the DSMB will be responsible for examining accumulated safety data, 
PK, and compliance data to make recommendations concerning the continuation, termination, or 
modification of the trial based on the safety of the interventions under study throughout the study.  
The DSMB will meet with a frequency as defined in the DSMB charter . 
Further information regarding the DSMB  review process  will be  provided in the DSMB  charter.  
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 47 9. STATISTICAL METHODS AND PLANNED ANALYSES  
9.1. General Considerations  
A Statistical Analysis Plan ( SAP), in compliance with the  International Council for Harmonisation  
(ICH) and Food and Drug Administrationâ€™s Guidance for Industry: â€œ Statistical Principles for Clinical 
Trials â€, will be written and finalized prior to database lock and unblinding providing greater detail on 
the statistical analysis  methodology. 
All eCRF data, as well as any outcomes derived from the data, will be displayed in data listings .   
Descriptive characteristics for continuous variables will be summarized using mean, median, standard 
deviation, minimum and maximum values.  For categorical variables, the number and percentage of patients (or observations) will be reported.  
Unless otherwise defined for a particular endpoint, a patientâ€™s baseline value is the last measurement 
prior to initiation of study drug. 
9.2. Determination of Sample Size  
Approximately 126 patients will be  enrolled and assigned to either edasalonexent or placeb o in a 
2:1 ratio.  Based on Phase 1/2 data of changes in NSAA in this age group, an effect size of 0.625 is 
assumed.  With this effect size, and assuming a dropout rate of approximately 20%, the study ha s 
approximately 80% power to show a difference between the treatment groups at a 2 -sided type I error 
rate of  0.05.   
The number of enrolled patients on eteplirsen should not exceed their representation in the Duchenne 
population. 
9.3. Analysis Sets  
The following are the analysis populations for this study: 
Randomized Population:  The Randomized Population consists of all patients who are randomized 
into the study.  
Note : If a randomized patient has a sibling assigned to the same treatment group, the non-randomized 
sibling (i.e., the sibling assigned to the s ame treatment as the randomized sibling) will not be included 
in the randomized population (see Section  5.5.1).   
Safety Population:  T he Safety Population will consist of all patients who receive at least 1  dose of 
study drug.  This will include the set of patients who were assigned the same treatment as their 
randomized sibling.   
Full Analysis Population:  The Full Analysis Population for efficacy a nalyses will be a modified 
intent to treat (mITT) population and will consist of all patients in the Randomized Population who 
receive at least 1  dose of study drug, and provide at least 1 valid post Baseline NSAA efficacy 
assessment.   
Per Protocol Popula tion:  The Per Protocol (PP) P opulation will consist of all patients in the Full 
Analysis Population who complete the study, without any significant protocol violations.   
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 48 PK Population:  T he PK P opulation will consist of all patients in the Safety Population who receive at 
least 1  dose of edasalonexent and have at least 1  measured plasma concentration .   
Other analysis populations may be defined in the SAP.   
9.4. Demographics and Baseline Characteristics  
Demographics, including age at Baseline considered as a continuous variable, frequency of age by 
year, age at Baseline (â‰¤ 6.0 years or >6.0 years ) and Baseline characteristics , including time to stand 
from supine (â‰¤5 seconds or >5 seconds) treatment with eteplirsen  (yes or no), and region (North 
America or Europe/ Asia/Australia ) will be listed by patient, and summarized by treatment group and 
overall .   
9.5. Concomitant Medications  
Concomitant medications will be listed by treatment and coded using the WHO Drug dictionary.  
9.6. Medical History  
Medical history will be listed and coded by patient using the Medical Dictionary for Regulatory 
Activities (MedDRAÂ®) dictionary  Version 21.0. 
9.7. DMD-Specific Medical History  
DMD-specific medical history, including age at symptom onset and diagnosis, will be listed by 
patient, and summarized by treatment group and overall .   
9.8. Patient Disposition  
All patients who sign the informed consent will be included in a summary (s) of patient disposition.  
The number of patients randomized , and the number and percentage of patients discontinuing and 
completing treatment, will be presented .  The number of patients discontinuing before study 
completion (including reason for discontinuation), and the number of patients completing the study will be presented  as well .  The number and percentage of patients in the various analysis populations 
will be presented separately.  
9.9. Study Treatment Usage and Compliance  
For the Safety Population, treatment duration, number of administrations, and compliance will be 
summarized by treatmen t group and overall .   
9.10. Efficacy Analyses  
Results of efficacy assessments will be listed by patient, and summarized by treatment group and 
timepoint, as applicable.  For the TFTs , both the times to complete in  seconds and their speed (i.e., 
the reciprocals ) will be tabulated  (in the case of the 10MWT, in units of 10 meters per second; in the 
case of the stand from supine and 4-stair climb in units of task per second).  Descriptive statistics will 
be calculated for quantitative efficacy data as well as for the CFB , and differences between groups as 
applicable. 
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 49 9.10.1. Primary Efficacy Endpoint 
The primary efficacy endpoint will be the CFB  in the NSAA Total Score at Week  52. 
The CFB in NSAA Total Score will be analyzed using a mixed -model repeated -measures (MMRM) 
analysis of covariance (ANCOVA), implemented using SASÂ® Proc Mixed .  The factors in the model 
will be Baseline age (â‰¤ 6.0 years or >6.0 years) , time to stand from supine (â‰¤5 seconds or >5 seconds), 
region (North America or Europe/ Asia/Australia ), visit, tre atment group, Baseline value, Baseline 
value by visit, and treatment group by visit. 
The primary analysis will test the treatment difference at Week  52 via the MMRM model at the two -
sided 0.05 level.  Details of the MMRM model will be provided in the SAP. The primary analysis 
will be performed on the Full Analys is Population with exclusions that may be defined in the SAP, 
such as excluding patients receiving treatment with eteplirsen. 
9.10.2. Secondary  Efficacy Endpoints  
The secondary efficacy endpoints will be the CFB  to Week  52 on the 10MWT, stand from supine,  
and 4- stair climb . 
The Baseline values and CFB in each will be summarized by treatment group and timepoint using 
descriptive statistics .  The CFB will be analyzed using the same MMRM ANCOVA model as 
described above for the primary efficacy endpoint. The secondary efficacy analys es will be performed 
on the Full Analysis Population with exclusions that may be defined in the SAP, such as excluding 
patients receiving treatment with eteplirsen.  
9.10.3. Controlling for Multiplicity  
The method for controlling the overall Type I Family -wise error rate at the two -sided 0.05 level will 
be provided in the SAP. 
9.10.4. Sensitivity Analyses of the Primary and Secondary Efficacy Endpoints  
Sensitivity analys es of the primary and secondary efficacy endpoints will be specified in the SAP .   
While the MMRM analysis represents the primary method for incorporating patients with missing 
data (i.e., observed case analyses), a multiple  imputation method for addressing missing data will be 
applied using the primary and secondary analysis methods.   
Additional details on the methods to assess the impact of missing data will be provided in the SAP. 
9.10.5. Additional  Efficacy Endpoints  
Additional efficacy endpoints will include CFB on the following endpoints: 
â€¢ Muscle strength testing  
â€¢ PUL  entry item assessment 
â€¢ PODCI  Transfer and Basic Mobility scale 
The analysis methods for these endpoints will be defined in the SAP.  Additional efficacy  endpoints 
may also  be defined in the SAP. 
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 50 9.11. Pharmacokinetic  Analyses  
Serial plasma concentration time data collected for edasalonexent and its metabolites will be analyzed 
using non- compartmental methods for all patients with evaluable data.  Actual sample and dosing 
times will be used for pharmacokinetic analyses. Pharmacokinetic parameters, as data permit, will be 
reported for individual patients and summarized using descriptive statistics by visit. Trough 
concentrations will be summarized separately, along with other single time -point plasma 
concentration data by visit. Exploratory PK- PD analyses may be performed as deemed necessary.  
In addition to non-compartmental analyses or when the data do not lend to a non- compartmental 
approach, pharmacokinetic data will be analyzed using non- linear mixed -effects modeling approach 
for population pharmacokinetic analyses. For population PK analyses, data from this clinical study 
will be pooled with data from other clin ical studies with extensive and/or sparse sampling. The 
population PK analyses will characterize the inter - and intra- subject variability in pharmacokinetic 
parameters and evaluate the effect of covariates such as but not limited to, demographics (e.g., age, body weight, race), disease status on oral clearance and volume. Exploratory population PK- PD 
analyses may also be performed to evaluate and characterize exposure-response relationships. 
As an exploratory analysis, urine samples will be analyzed in terms of concentrations of 
edasalonexent and/or metabolites.  
Raw and derived data will be summarized using descriptive statistics and presented graphically, as appropriate.  Plasma  PK parameters will be estimated from plasma concentration -versus- time data 
using noncompartmental analyses.   
The following noncompartmental PK parameters will be calculated from plasma samples: 
â€¢ Area under concentration  time curve from time 0 to time of last quantifiable concentration 
(AUC
last) 
â€¢ Area under concentration time curve fro m time 0 to 4 hours post dosing ( AUC 0-4) 
â€¢ Maximum plasma concentration (C max) 
â€¢ Last quantifiable plasma concentration (C last) 
â€¢ Time of C max (Tmax) 
â€¢ Time of C last (Tlast) 
â€¢ Time between the time of dosing and time of appearance of plasma concentration (T lag) 
The detailed methodology will be described in the SAP. 
9.12. Safety Analyses  
Safety will be assessed using the incidence of treatment -emergent AEs and SAEs, physical 
examination findings, growth parameters, vita l signs, clinical laboratory evaluations, and  ECGs .   
Results of all safety assessments will be liste d by patient, and summarized by treatment group and 
timepoint as applicable .  
These safety analyses will be compared qualitatively between groups; however, there will be no 
inferential statistical comparisons between  groups. 
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 51 9.12.1. Physical Examination, Growth Parameters, Electrocardiograms,  and Vital Signs  
Physical examination  (general appearance, skin, HEENT, etc. ) abnormal results  will be summarized .  
Physical examination results will also be summarized in a shift table from Baseline. 
Growth parameters (height, weight, BMI) will be compared to age- normative percentiles.  
ECG results will be summarized at each timepoint, and also using shift tables from Baseline. 
Vital signs (temperature, heart rate, respiratory rate, and systolic and diastolic blood pressure) , and 
changes from Baseline in vital signs,  will be summarized descriptively at Baseline and other study 
timepoints.  Data listings will be provided. 
9.12.2. Clinical Laboratory Tests 
Values at all study timepoints and changes from Baseline to post Baseline timepoints in clinical 
chemistry, hematology and urinalysis results will be summarized descriptively .  Shift tables from 
Baseline to each timepoint and from Baseline to each patientâ€™s final visit will be produced by cohort 
and overall.   
Abnormal clinical laboratory values will be identified as outside (above or below) the normal range 
and will be evaluated for clinically notable abnormalities .  Reference (normal) ranges for laboratory 
parameters will be included in the clinical study report.   
9.12.3. Adverse Events  
Adverse events will be coded using the MedDRAÂ® dictionary and will be categorized by system 
organ class  (SOC) and preferred term.  
An overall summary of TEAEs will include the number and percentage of patients in each cohort and 
overall reporting: 
â€¢ Any TEAEs  
â€¢ Treatment -related TEAEs  
â€¢ Severe TEAEs  
â€¢ Serious TEAEs, including any events resulting in death 
â€¢ Treatment -related serious TEAEs  
â€¢ TEAEs (and treatment -related TEAEs ) leading to discontinuation of study drug 
TEAEs will be summarized by SOC and preferred term , with each patient counted only once for each 
AE reporting level.  TE AEs will also be summarized by SOC, preferred  term , and severity and by 
SOC, preferred term , and relatedness .  The most severe occurrence of a TEAE, as well as the most 
extreme relationship of the TEAE to the study procedures or treatment, will be used in tabulations of severity  and relatedness  in cases of multiple occurrences of the same TEAE.   
9.13. Pharmacodynamic Analyses  
Pharmacodynamic analyses may include  evaluation of gene expression as well as circulating protein 
and micro -RNA biomarkers that help inform target engagement and  efficacy .  These will be assessed 
at the times specified in  Appendix 1.  Blood samples will also be collected at times specified in 
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 52 Appendix 1  for pharmacogenomic studies that might predict the course of disease and/or response to 
treatmen t as well as analy sis of drug metabolizing enzyme and/or transporters.   
9.14. Cardiac Monitoring  
Measures of cardiac autonomic dysfunction, including heart rate variability, will be measured at the 
times specified in  Appendix 1.  Results will be summarized by treatment group and timepoint as 
applicable.  
The detailed analyses will be provided in the SAP.  
9.15. Bone Evaluations  
Lateral thoracolumbar spin e radiography scans and DXA scans will be performed at the times 
specified in  Appendix 1. Bone radiography will be locally read and centrally evaluated. 
Results will be summarized by treatment group and timepoint as applicable.  The detailed analyses will be provided in the SAP.  
9.16. Other Statistical Issues  
9.16.1. Missing or Invalid Data 
For the primary and secondary efficacy analyses, the MMRM analyses will be observed case 
analyses.  Multiple imputation will be used as a sensitivity analysis to address missing data (see 
Section  9.10.4) ; additional methods will be specified in the SAP.  
If a patient is  not able to complete a TFT , a value of 0  tasks/sec ond will be assigned . 
If a patient initiates corticosteroid therapy or discontinues study treatment, all observations from a 
patient after these events will be  censored from the primary and secondary efficacy analyses.  
Sensitivity analyses which incorporate these observations will be defined in the SAP. 
9.16.2. Multi site Issues   
Summary statistics for the primary and secondary efficacy endpoints will be presented by 
investigative site . 
9.16.3. Subgroup Analyses  
The SAP will address analyses of  additional subgroups. 
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 53 10. SPECIAL REQUIREMENTS  AND PROCEDURES  
This protocol was designed and will be conducted, recorded, and reported in compliance with the 
ICH/Good Clinical Practice (GCP ) guideline.  These requirements are stated in the ICH Guideline 
Topic E6 entitled â€œGuideline for Good Clinical Practiceâ€.  
10.1. Instit utional and Ethics Review  
This protocol and a patient informed consent form, participant- facing  information sheets, and any 
proposed advertising materials, must be reviewed and approved by an IRB/IEC, applicable regulatory authorities, and host institution(s) for written approval ( where applicable) before enrollment of 
patients and release of investigational product.  Documentation of IRB/IEC approval and the 
approved consent form must be received by the Sponsor or its designee prior to obtaining the 
patientâ€™s informed consent.  These documents will also be submitted to and approved by the above 
parties for all substantial amendments to the original approved documents, where applicable. 
10.2. Changes to the Conduct of the Study or Protocol  
Any changes in the study protocol, such as changes in the study design, objectives or endpoints, 
inclusion and exclusion criteria, and/or procedures ( except to eliminate an immediate hazard ) will be 
implemented only after the mutual agreement of the Investigator and the Sponsor or designee.  All 
protocol changes must be documented in protocol amendment(s).  Protocol amendment (s) must be 
signed by the Investigator and approved by the IRB/IEC and Competent Authorities ( CA), if 
applicable, prior to implementation .  Any changes in study conduct that result from a pending 
amendment will be considered protocol deviations until required IRB/IEC/CA approvals are granted.  
Documentation of IRB/IEC/CA approval ( as applicable) must be returned to the Sponsor or designee.  
10.3. Investigatorâ€™s Responsibilities  
10.3.1. Patient Informed Consent  
Investigators must adhere to GCP, which includes ethical principles that have their origin in the Declaration of Helsinki, when developing the patient informed consent form and when obtaining consent from the pati ent.  Written informed consent from the parent or legal guardian of the patient 
(and written  assent  for pediatric patients as per regional and/or IRB/IEC requirements ) is required 
prior to enrollment in the study.  It is the responsibility of the Investigator to document the consent process within the source documents and obtain consent using an IRB- /IEC -approved consent form. 
10.3.2. Case Report Forms  
Copies of pertinent records relevant to  the study, including all source documents, will be made 
available to the S ponsor or its designee on request with due precaution towards protecting the privacy 
of the patient. 
Data will be entered by the site onto the eCRFs in the EDC system.  Unless explicitly directed, blank 
data fields are not acceptable.  Any erroneous entries made on the eCRFs should be corrected.  Changes made to the data after initial entry into the eCRF will be captured via an electronic audit 
trail, and should include the reason for change.  Incomplete entries or entries needing additional 
explanation will be highlighted or queried to the Investigator for clarification. 
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 54 10.3.3. Record Retention  
The enrolling Investigator is responsible for oversight and maintenance of the study records and 
patient source documents unless the patient is transferred to another site for all subsequent visits.  
These records must be readily available for audit or inspection. 
The Investigator must retain study records for at least 2 years after the last marketing approval has 
been granted, or at least 2 years have elapsed s ince the formal discontinuation of clinical program.  
However, these documents should be retained for a longer period, if required by other applicable 
requirements (e.g., applicable local regulatory requirement) or by an agreement with the Sponsor or 
its designee.  The Investigator should contact the Sponsor or its designee prior to any record 
destruction. 
Patient records or other source data must be kept for the maximum period of time mandated by the 
hospital, institution, or private practice, but not less than 15 years.  
If off -site archiving is used, all records should be retrieved and made available for review at the time 
of an audit or regulatory authority inspection. 
10.3.4. Monitoring  
A representative of the Sponsor or its designee will visit the Investigator periodically for the purpose 
of monitoring the progress of this study in accordance with the protocol, GCP, and local regulations.  Noncompliance with the protocol, GCP, and local regulations will be documented and corrective 
actions implemented, as necess ary.  It is the responsibility of the Investigator to be present or 
available for consultation during monitoring visits .  During these routine visits, all data pertaining to a 
patientâ€™s participation in this clinical investigation must be made available to  the monitor. 
Monitoring during the COVID-19 pandemic is subject to Investigator and/or local restrictions. It is 
possible that after local restrictions are lifted, monitoring may resume with more intense pace to clean all data accumulated during the pande mic.   
At any time prior to, during, or after completion of the clinical study, an audit may be performed by the Sponsor or its designee or a representative of a national regulatory agency may choose to inspect a study site.  Investigators should notify the Sponsor or its designee upon notification of inspection by 
a representative of a national regulatory agency .  A Sponsor or designee representative will be 
available to assist in the preparation for study site inspections.  All pertinent study data should be 
made available for verification, audit, or inspection purposes. 
10.3.5. Study or Site Termination 
If the Sponsor, the Investigator, or regulatory authorities discover any conditions during the study that 
indicate that the study or study site should be terminated, this action may be taken after appropriate consultation between the Sponsor and the Investigator.  The Sponsor has the right to terminate the 
participation of either an individual site or the study at any time, for any reason, which may include 
the following: 
â€¢ The incidence and severity of AEs in this or other studies indicates a pote ntial health 
hazard to patients  
â€¢ Patient enrollment is unsatisfactory  
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 55 â€¢ Data recording is inaccurate or incomplete.  
â€¢ Investigator(s) does  not adhere to the protocol or applicable regulatory guidelines in 
conducting this study 
â€¢ Submission of knowingly false information from the study site to the Sponsor or 
regulatory authorities 
In the event that the study is terminated early, the Sponsor will provide specific guidance to investigational sites regarding the end-of-study procedures. 
10.3.6. Investigational Product Control 
10.3.6.1. Receipt of Investigational Product 
A proof of receipt, which details the quantity and description of the investigational product, will 
accompany the shipment from the Sponsor or designee to the Investigator.  The site must 
acknowledge each shipment of investigational product in the IWRS system once received. The 
Investigator must ensure that the investigational product is maintained in a controlled location, with 
limited access, and under adequate storage conditions (as described in Section  5.1.4) . 
10.3.6.2. Disposition of Unused Investigational Product 
All unused investigational products must be maintained under adequate storage conditions in a limited -access area.  If any unused material is remaining upon completion of the study, the material 
will be returned to the Sponsor or destroyed only after the following has been completed: 
â€¢ Accountability has been performed by a representative of the Sponsor. 
â€¢ Approval to return or destroy unused Investigational Product.  Refer to the SDHM for 
further details . 
10.3.6.3. Product Handling and Complaints Reporting  
If there are any issues during the study related to the quality of the Investigational Product, the 
clinical site pharmacist or pharmacy designee should con tact the Sponsor. 
10.3.7. Disclosure of Data  
All details related to the disclosure and publication of study data will be addressed in the Investigatorâ€™s study contract.   
10.3.8. Confidentiality and Data Privacy    
Personal data recorded on all documents will be regarded as strictly confidential and will be handled 
and stored in accordance with the General Data Protection Regulation (GDPR 25May2018) in 
European Union Member States.  
Sponsor affirms the patient's right to protection against invasion of privacy and to be in compliance 
with ICH and other local regulations (whichever is more stringent). Sponsor requires the Investigator 
to permit sponsor representatives (monitor) and when necessary, representatives from regulatory authorities, to review and/or copy any medical records relevant to the study in accordance with local laws (any copies of patientsâ€™ records must be duly anonymised to protect patientsâ€™ confidentiality).  
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 56 Should direct access to medical records require a waiver or authorisation separate from the patient â€™s 
statement of informed consent, it is the responsibility of the Investigator to obtain such permission in 
writing from the appropriate individual. Representative of the sponsor may be required to have access to patientâ€™s medical records for quality assurance purposes but patients should be reassured that their confidentiality will be respected at all times.  
Representative of sponsor must maintain the confidentiality of all patientâ€™s data and will not disclosed information by which patients may be identified to any third party other than those directly involved in the treatment and organization for which the patient has given explicit consent for data transfer. 
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 57 11. REFERENCES 
 
Arpan, I., R. J. Willcocks, et al. (2014). Examination of effects of corticosteroids on skeletal muscles 
of boys with DMD using MRI and MRS. Neurology 83(11): 974-980. 
Beenakker, E. A., N. M. Maurits, et al. (2005). Functional ability and muscle force in healthy children and ambulant Duchenne muscular dystrophy patients. Eur J Paediatr Neurol  9(6): 387-393. 
Birnkrant, D. J., K. Bushby, et al. (2018a). Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and ort hopaedic management. The Lancet 
Neurology. 
Birnkrant, D. J., K. Bushby, et al. (2018b). Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional managemen t. The Lancet Neurology 17 (3): 251-267. 
Blake, D. J., A. Weir, et al. (2002). Function and genetics of dystrophin and dystrophin- related 
proteins in muscle. Physiol Rev 82(2): 291-329. 
Cai, D., J. D. Frantz, et al. (2004). IKKbeta/NF-kappaB activation caus es severe muscle wasting in 
mice. Cell  119(2): 285-298. 
Donovan, J. M., M. Zimmer, et al. (2017). A Novel NF- kappaB Inhibitor, Edasalonexent (CAT -
1004), in Development as a Disease-Modifying Treatment for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult Subjects. J Clin 
Pharmacol  57(5): 627-639. 
Emery, A. E. (2002). The muscular dystrophies. Lancet  359(9307): 687-695. 
Griggs, R. C., R. T. Moxley, 3rd, et al. (1990). Randomized, double- blind trial of mazindol in 
Duchenne dystrophy. Muscle Nerve 13(12): 1169-1173. 
Hammers, D. W., M. M. Sleeper, et al. (2016). Disease-modifying effects of orally bioavailable NF-kappaB inhibitors in dystrophin- deficient muscle. JCI Insight  1(21): e90341. 
Hanaoka, B. Y., C. A. Peterson, et al. (2012). Implications of glucocorticoid therapy in idiopathic inflammatory myopathies. Nat Rev Rheumatol  8(8): 448-457. 
Henricson, E., R. Abresch, et al. (2013). The 6-minute walk test and person-reported outcomes in boys with duchenne muscular dystrophy and typically developing controls: longitudinal comparisons and clinically -meaningful changes over one year. PLoS Curr 5. 
Howie, S. R. (2011). Blood sample volumes in child health research: review of safe limits. Bull 
World Health Organ  89(1): 46-53. 
Hu, X. and S. S. Blemker (2015). Musculoskeletal simulation can help explain selective muscle degeneration in duchenne muscular dystrophy. Muscle Nerve. 
Kinali, M., V. Arechavala-Gomeza, et al. (2009). Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, 
dose-escalation, proof- of-concept study. Lancet Neurol  8(10): 918-928. 
King, W., R. Ruttencutter, et al. (2007). Orthopedic outcomes of long- term daily corticosteroid 
treatment in Duchenne muscular dystrophy. Neurology 68(19): 1607-1613. 
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 58 Kohler, M., C. F. Clarenbach, et al. (2009). Disability and survival in Duchenne muscular dystrophy. 
J Neurol Neurosurg Psychiatry 80(3): 320-325. 
Kopp, E. and S. Ghosh (1994). Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 
265(5174): 956-959. 
Li, H., A. Mittal, et al. (2009). Matrix metalloproteinase-9 inhibition ameliorates pathogenesis and improves skeletal muscle regeneration in muscular dystrophy. Hum Mol G enet 18(14): 2584-2598. 
Manzur, A. Y., T. Kintzer, et al. (2009). Glucocorticoid corticosteroids for Duchenne muscular dystrophy. The Cochrane Library . 
Mayhew, A., E. S. Mazzone, et al. (2013a). Development of the Performance of the Upper Limb module for Duchenne muscular dystrophy. Developmental Medicine & Child Neurology 55(11): 
1038-1045. 
Mayhew, A. G., S. J. Cano, et al. (2013b). Detecting meaningful change using the North Star Ambulatory Assessment in Duchenne muscular dystrophy. Dev Med Child Neurol 55(11): 1046-
1052. 
Mazzone, E., G. Vasco, et al. (2011). Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study. Neurology 77(3): 250-256. 
McDonald, C. M., E. K. Henricson, et al. (2018). Long- term effects of glucocorticoids  on function, 
quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. The Lancet  391(10119): 451-461. 
Mendell, J. R., R. T. Moxley, et al. (1989). Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med 320(24): 1592-1597. 
Mercuri, E., C. McDonald, et al. (2012). International workshop on assessment of upper limb function in Duchenne Muscular Dystrophy: Rome, 15-16 February 2012. Neuromuscul Disord 
22(11): 1025-1028. 
Newton, R. and N. S. Holden (2007). Separating transrepression and transactivation: a distressing divorce for the glucocorticoid receptor? Mol Pharmacol  72(4): 799-809. 
Pane, M., G. Coratti, et al. (2018). Upper limb function in Duchenne muscular dystrophy: 24 month longitudinal data. PLOS ONE  13(6): e0199223. 
Pane, M., L. Fanelli, et al. (2015). Benefits of glucocorticoids in non-ambulant boys/men with Duchenne muscular dystrophy: A multicentric longitudinal study using the Performance of Upper Limb test. Neuromuscul Disord 25(10): 749-753. 
Pane, M., E. S. Mazzone, et al. (2014a). Reliability of the Performance of Upper Limb assessment in Duchenne muscular dystrophy. Neuromuscular Disorders 24(3): 201-206. 
Pane, M., E. S. Mazzone, et al. (2014b). Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes. PLoS One 9(10): e108205. 
Porter, J. D., A. P. Merriam, et al. (2003). Dissection of temporal gene expression signatures of affected and spared muscle groups in dystrophin- deficient (mdx) mice. Hum Mol Genet  12(15): 
1813-1821. 
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 59 Schacke, H., A. Schottelius, et al. (2004). Dissociation of transactivation from transrepression by a 
selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci U S A  101(1): 227-232. 
Schakman, O., H. Gilson, et al. (2009). Mechanisms of muscle atrophy induced by glucocorticoids. Horm Res  72 Suppl 1 : 36-41. 
Scott, E., M. Eagle, et al. (2012). Development of a functional assessment scale for ambulatory boys with Duchenne muscular dystrophy. Physiother Res Int 17(2): 101-109. 
Seferian, A. M., A. Moraux, et al. (2015). Upper limb strength and function changes during a one-year follow-up in non-ambulant patients with Duchenne Muscular Dystrophy: an observational multicenter trial. PLoS One 10(2): e0113999. 
Thomas, T. O., J. L. Jefferies, et al. (2015). Autonomic dysfunction: a driving force for myocardial fibrosis in young Duchenne muscular dystrophy patients? Pediatr Cardiol  36(3): 561-568. 
Thomas, T. O., T. M. Morgan, et al. (2012). Correlation of heart rate and cardiac dysfunction in Duchenne muscular dystrophy. Pediatr Cardiol  33(7): 1175-1179. 
Vu, C. B., J. E. Bemis, et al. (2016). Synthesis and Characterization of Fatty Acid Conjugates of Niacin and Salicylic Acid. J Med Chem  59(3): 1217-1231. 
Willcocks, R. J., I. A. Arpan, et al. (2014). Longitudinal measurements of MRI-T2 in boys with Duchenne muscular dystrophy: effects of age and disease progression. Neuromuscul Disord 24(5): 
393-401. 
Yin, M. J., Y. Yamamoto, et al. (1998). The anti- inflammatory agents aspirin and salicylate inhibit 
the activity of I(kappa)B kinase- beta. Nature 396 (6706): 77-80. 
Zwart, S. R., D. Pierson, et al. (2010). Capacity of omega-3 fatty acids or eicosapentaenoic acid to counteract weightlessness -induced bone loss by inhibiting NF-kappaB activation: from cells to bed 
rest to astronauts. J Bone Miner Res 25(5): 1049-1057
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 60 APPENDIX  1. SCHEDULE OF ASSESSME NTS 
 Screen a BL b Double Blind, Placebo -Controlled Treatment (Weeks 1 - 52) Safety F/U c 
Study Week(s)  -4 - 0 0 6 13 19 26 32 39 45 52/ETd   
Informed Consent/Assent  X           
Site Visit e  X X  X  X  X  X  
Site Call  e, f   X  X  X  X  X 
Med History/Demographics  X           
Confirm Eligibility  X X          
Randomization g  X          
Vital Signs  X X  X  X  X  X  
Weight  X X  X  X  X  X  
Height   X    X    X  
Physical Examination  X X  X  X  X  X  
AEs/Con Medsh  X Continuous  
12-Lead ECGi  X     X    X  
Cardiac Monitoring j X     X    X  
Hematology/Chemistry k X X  X  X  X  X  
ACTH/Cortisol k   X  X  X  X  X  
Urinalysis  X     X    X  
DNA Sample l  X          
Biomarkers, Gene Expression k  X  X  X  X  X  
NSAA, Stand from Supine, 10MWT,  
4-Stair Climb, Muscle Strength m X X  X  X  X  X  
PUL n  X    X    X  
Videotape Functional Assessments o X X        X  
PODCI p  X        X  
Lateral Spinal Radiography, DXA q  X        X  
Study Drug Questionnaire       X      
Nutritional Guidance r  X          
Drug Dispensation   X  X  X  X    
Drug Accountability     X  X  X  X  
PK (plasma and urine) s    X  X    X  
 
a Per Investigatorâ€™s discretion, informed consent, medical history/demographic data and lab assessments may be completed remotely by a qualified medical professional.  
b The first day of study drug is â€œDay 1â€; unless otherwise specified, all assessments should be completed within a 4 week window prior to Day 1.  
c Safety follow -up should occur within 2 wks . after last dose of study drug.  Patients continuing in the open- label extension study are not required to perform the safety follow -up. 
d If patient discontinues treatment early, patient will be asked to return for early termination (ET) visit prior to their last dose of study drug.  Functional assessments performed 
within 6 weeks of discontinuing treatment do not need to be repeated at the ET visit.  If the ET visit occurs after drug has been discontinued, certain assessments may be omitted 
per Sponsor discretion.  
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary 61 e Weeks 6 -19 should be conducted within the study week with a Â±4- day window.  W eeks 26 -54 have a Â±10-day window . 
, f Per Investigator discretion, site calls may occur by teleph one or use of other technology.  
g Randomization occurs after Screening assessments have been completed and eligibility is confirmed.  
h AEs and concomitant medication/therapy will be assessed at all visits and during site calls.  
i ECGs will be performed predose at all timepoints. At Week 26, ECG will per performed predose and 2 hours postdose (+/ -15 min).  
j Cardiac monitoring will be performed for  approximately  48 hours remotely via a wearable cardiac monitoring device if approved for use in the participating country.  
k Blood samples will be drawn  in the morning when possible.  
l DNA sample may be collected at Baseline for drug metabolizing enzyme and/or transporter analysis as well as pharmacogenomic analysis of potential markers of clinical 
risk/benefit.  
m Assessments should be performed in the order listed and in the morning when possible.  Time to stand from supine and 10MWT will be recorded as measured in the N SAA.  
n The PUL 6 -point entry item scale will be performed at all timepoints.  If a patient scores a 6 on the PUL entry item scale,  no further PUL testing is required for the visit.  
o  Videotaping at Baseline is required if Screening video did not pass QC.   
p PODCI will be performed when feasible.  
q These assessments should be collected within 2 months prior to Day 1. In Germany, bone assessment will not be performed until the respective approvals from the German Federal Office for Radiation Protection (Bundesamt fÃ¼r Strahlenschutz) become available.  
r Patient compliance with the nutritional guidance will be confirmed throughout the t rial. 
s Urine PK collection will be performed at Week 13.  Plasma PK collection will be performed predose at Week 13 and Week 52.  At  Week 26 plasma PK collection will be 
performe d predose, 1 hour  (+/- 5 min) , 2 hours (+/ -15 min), and 4 hours  (+/- 15 min)  postdose.
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary  62 APPENDIX  2. POTENTIAL MODIFIC ATIONS TO THE SCHEDULE OF 
ASSESSMENTS  DURING THE COVID -19 PANDEMIC  
At the time of the COVID -19 pandemic, all enrolled patients had completed at least Week 26 so 
the implementation of alternative means to complete study assessments is intended for Week 39 
and Week 52 only.  
If the Investigator is able to perform the scheduled visit with out impact to the safety of the 
patients and their families  because of  the COVID -19 pandemic, the Investigator should perform  
study assessments on site according to Appendix 1.   
If the Investigator is unable or unwilling to perform the scheduled Week 52 visit within window 
without impact to the safety of the patients and their families because of the COVID -19 
pandemic, the Investigator, along with the patient/caregiver may decide to conduct the visit out of window (but in no case should the projected target date be changed by more than 2 months).    
The COVID -19 pandemic has impacted study sites variably, so individual situa tions at each site 
may impact the capabilities of sites to perform certain study assessments.  The purpose of 
Appendix 2 is to outline considerations f or sites to perform study procedures either on site or 
remotely by using alternative approaches to collect study assessments.  While some study 
assessments can be performed remotely, it is acknowledged that others are not feasible to be 
conducted remotely. As the top priority is safety, assessing for AE and concomitant medications is the highest priority 
to continue, which will occur remotely at intervals specified in Appendix 1.  Based on the safety 
profile of edasalonexent to date, and consideration that all patients in this study have been on 
study drug for 6 months, other safety assessments, including physical examinations, chemistry 
and hematology labs and urinalysis can be deferred for six-month intervals if not feasible given 
the COVID -19 pandemic.   
The next priority is study integrity, which requires continued administration of study drug and 
efficacy assessments.  Drug dispensation can take place according to local site procedures, 
including secured, temperature-controlled shipments to the patientsâ€™ homes.  Study drug 
accountability can be assessed remotely as well.   
Remote collection of efficacy measurements may occur if not feasible on site. Efficacy measurements collected remotely will be administered and monitored by trained evaluators. Additional details on the remote collection of efficacy measurements are provided in the Remote 
Efficacy Assessment Clinical Evaluator Manual developed  for Duchenne clinical trials during 
the COVID -19 pandemic.  Functional assessments may be limited by the remote testing 
environment.  
Some study assessments from Appendix 1 may be not included in Appendix 2 due to the 
Sponsorâ€™s assessment of patient safety vs. criticality during the COVID- 19 pandem ic.   
In the situation where the Investigator is able to perform study procedures on site but requires 
prioritization of study assessments to minimize patient time on site  or exposure to certain 
locations within the study location, the Investigator should prioritize  according to the outline 
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary  63 below. If a prioritized assessment cannot be performed, that does not preclude other assessments 
for the specific Visit in  Appendix 1 if feasible and without additional risk.  
 
â€¢ Week 39 Visit : performed on -site, priorities listed below  
âˆ’ Assess AE and Concomitant Medications 
âˆ’ Measure weight  (to re -supply study drug), perform study drug accountability, re -
supply Study Drug 
âˆ’ Perform Primary and Secondary Efficacy Assessments (NSAA, TFTs, PUL) 
âˆ’ Physical examination and vital signs 
âˆ’ Lab assessments:  chemistry, hematology, UA and  PK (drawn at the same time ) 
â€¢ Week 39 Visit: on- site visit is cancelled , priorities listed below  
âˆ’ Reconsent/assent for remote efficacy assessments   
âˆ’ Assess AE and Concomitant Medications 
âˆ’ Measure weight by home scale (to re-supply study drug), assess drug 
accountability  as appropriate, re -supply Study Drug via courier service  
âˆ’ Perform Primary and Secondary Efficacy Assessments (NSAA, TFTs, PUL) 
remotely requires videotaping. More detail can be found in the Remote Efficacy Assessment Clinical Evaluator Manual  
â€¢ Week 52 Visit : performed on -site, priorities listed below 
âˆ’ Assess AE and Concomitant Medications 
âˆ’ Perform Primary and Secondary Efficacy Assessments (NSAA, TFTs, PUL) 
âˆ’ Physical examination and vital signs, including height and weight 
âˆ’ Lab assessments:  chemistry, hematology, UA and  PK and biomarkers ( drawn at 
the same time ) 
âˆ’ ECG  
âˆ’ PODCI ( if time limitations, provide and collect at next opportunity ) 
âˆ’ DXA and lateral spine films ( recognizing that traveling to other parts of the clinic 
or hospital) may not be conducive at this time) 
â€¢ Week 52 Visit: on-site visit is cancelled , priorities listed below  
âˆ’ Reconsent/assent for remote efficacy assessments  
âˆ’ Assess AE and Concomitant Medications 
âˆ’ Perform Primary and Secondary Efficacy Assessments (NSAA, TFTs, PUL) remotely requires videotaping. More detail can be found in the Remote E fficacy 
Assessment Clinical Evaluator Manual  
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary  64 âˆ’ Measure weight by home scale and height as feasible.  
âˆ’ Perform d rug accountability as appropriate 
âˆ’ Lab assessments:  chemistry, hematology, UA to be considered via local labs but 
defer to I nvestigatorsâ€™ judgement and interval since most recent assessments  
âˆ’ PODCI ( provide electronically and collect at next opportunity 
 
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary  65 APPENDIX  3. LIST OF CLINICAL LABORATORY ASSESSMEN TS  
For timing of laboratory assessments, see Schedule of Assessments in Appendix 1   
Clinical Safety Assessments  
Clinical Chemistry  Urinalysis  Hematology 
Sodium 
Potassium  
Chloride Bicarbonate 
Total protein  
Albumin Creatine kinase  Calcium  
Phosphorus Glucose 
Blood urea nitrogen 
Creatinine  
Uric Acid  
Lactate dehydrogenase  
Total bilirubin ( direct  if above ULN) 
Alkaline phosphatase 
AST  
ALT  
GGT  
Cystatin C  
Cortisol (AM)  
ACTH  
Glutamate dehydrogenase Specific gravity  
pH Protein  
Glucose Ketones 
Bilirubin  
Blood 
RBCs  
WBCs  
Epithelial cells  
Bacteria  
Casts  
Crystals  WBC count 
RBC count 
Hemoglobin  
Hematocrit  
MCV, MCH, and MCHC  
Platelet count 
WBC differential (% and 
absolute) 
â€¢ Neutrophils 
â€¢ Lymphocytes  
â€¢ Monocytes 
â€¢ Eosinophils 
â€¢ Basophils 
 
 
ACTH=a drenocorticotropic hormone ; ALT=alanine aminotransferase; AST=aspartate aminotransferase; 
GGT=gamma-glutamyl transferase; MCH=mean corpuscular hemoglobin; MCHC=mean corpuscular hemoglobin 
concentration; MCV=mean corpuscular volume; RBC=red blood cell; ULN=upper level of normal; WBC=white blood cell  
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary  66 APPENDIX  4.    STUDY DRUG QUESTIONNAIRE  
 
                                            
Patient Initials  
|  |  |  | 
         Patient Study ID  
  |__|__|__| - |__ |__|__|  
 
 
           
      
     
 
       
 
  
STUDY DRUG QUESTIONNAIRE          
Protocol CAT- 1004- 301 
 
 
   09Jul2018  
 
 
Patient Initials ________           Subject ID: _ ______ - ____ ___          Date: _________________  
 
 This questionnaire should be completed by the caregiver of the patient. Please circle  the answer that most 
closely reflects the patientâ€™s  opinion of the study drug. Circle  only one answer per question.  
 
1. The taste and aftertaste  (a taste that remains in your mouth after swallowing)  of the study drug 
capsules  are acceptable:  
   
  
2. The smell of the study drug capsules  is acceptable:  
   
  
3. The size and shape of the study drug  capsules  are acceptable:  
 1 2 3 4 5 
Strongly Agree  Agree  Neither Agree Nor 
Disagree  Disagree  Strongly Disagree  
1 2 3 4 5 
Strongly Agree  Agree  Neither Agree Nor 
Disagree  Disagree  Strongly Disagree  
1 2 3 4 5 
Strongly Agree  Agree  Neither Agree Nor 
Disagree  Disagree  Strongly Disagree  
Clinical Trial Protocol:  CAT -1004-301 16 April 2020 
Confidential and Proprietary  68 APPENDIX  5.   PEDIATRIC OUTCOMES QUESTIONNAIRE (PODCI ) 
 
 
 
  
Pediatric  
Outcomes Questionnaire 
 
 
  
Developed by: 
American Academy of Or thopaedic SurgeonsÂ® 
Pediatric Orthopaedic Society of North America 
American Academy of Pediatrics Shrinerâ€™s Hospitals  
To be completed by the parent for children 2 â€“ 10 years old  
 
  
 
 Based on the Version 2.0 Pediatrics -Parent/Child Outcomes Intrument 
  
Also commonly referred to as the PODCI ("Pedi atric Outcomes Data Collection Instrument") 
  Revised, renumbered, reformatted August 2005 
 
 
Pediatric Outcomes Instrument: Page 2 of 8 Pediatric Health Assessment (parent-re ported) 
 
FOR OFFICE USE ONLY  
 Clinic ID    First six letter of patientâ€™s last name    
 Physician ID   Office Chart #   
 
 Diagnosis & ICD-9 Code*  Procedure & CPT Code  CPT Date  Side of body 
procedure was 
performed on:  
Primary DX  DX  
 
ICD-9  Tx   
ICD-9   â–¡ Right     â–¡ Left  
â–¡ Both      â–¡ N/A  
Secondary DX  DX   
ICD-9  Tx   
ICD-9   â–¡ Right     â–¡ Left  
â–¡ Both      â–¡ N/A  
Secondary DX  DX   
ICD-9  Tx   
ICD-9   â–¡ Right     â–¡ Left  
â–¡ Both      â–¡ N/A  
Secondary DX  DX   
ICD-9  Tx   
ICD-9   â–¡ Right     â–¡ Left  
â–¡ Both      â–¡ N/A  
Secondary DX  DX   
ICD-9  Tx   
ICD-9   â–¡ Right     â–¡ Left  
â–¡ Both      â–¡ N/A  
 
 
 
Pediatric Outcomes Instrument: Page 3 of 8 Pediatric Health Assessment (parent-re ported) 
 
 
Todayâ€™s Date   /   / 
 
Thank you for completing this questionnaire!  
 This questionnaire will help us to better understand your general health and any problems related to bone and muscle conditions.  
 
Your completion of this questionnaire is completely voluntary and your responses will be held in  the strictest confidence.  
 Please answer every question. Some questions may look like others, but each one is different.  
 
There are no right or wrong answers. If you are not sure how to answer a question, just give the best answer you can. You 
can make comments in the margin. We do read all your 
comments, so feel free to make as many as you wish.  
Your Child's Birth Date   /   / 
 
Your Child's Social Security Number ___________________ 
Your Social Security Number ______________________ 
 
 
Pediatric Outcomes Instrument: Page 4 of 8 Pediatric Health Assessment (parent-re ported) 
 
 
Some kind of problems can make it hard to do many acti vities, such as eating, bathing, school work, and playing 
with friends. We would like to find out how your child is doing. (Circle one response on each line.)  
 
During the last week  was it easy or hard for your child to:  
 
  Easy A little 
hard Very hard Can't do 
at all Too young for 
this activity 
1. Lift heavy books? 1 2 3 4 5 
2. Pour a half gallon of milk? 1 2 3 4 5 
3. Open a jar that has been opened 
before? 1 2 3 4 5 
4. Use a fork and spoon? 1 2 3 4 5 
5. Comb his/her hair?  1 2 3 4 5 
6. Button buttons?  1 2 3 4 5 
7. Put on his/her coat? 1 2 3 4 5 
8. Write with a pencil? 1 2 3 4 5 
 
 9.  On average, over the last 12 months
, how often did your child miss school (preschool, day care, camp, etc.) 
because of his/her health?  
 
1. Rarely 
2. Once a month 3. Two or three times a month 
4. Once a week 
5. More than once a week 6. Does not attend school, etc. 
 
During the last week
  how happy has your child been with: (Circle one response on each line.)  
 
  Very 
happy Somewhat 
happy Not sure Somewhat 
unhappy Very 
unhappy Child is 
too young 
10. How he/she looks? 1 2 3 4 5 6 
11. His/her body? 1 2 3 4 5 6 
12. What clothes or shoes he/she can 
wear? 1 2 3 4 5 6 
13. His/her ability to do the same things 
his/her friends do? 1 2 3 4 5 6 
14. His/her health in general? 1 2 3 4 5 6 
 
 
Pediatric Outcomes Instrument: Page 5 of 8 Pediatric Health Assessment (parent-re ported) 
During the last week , how much of the time: 
(Circle one response on each line.) 
 
  Most of 
the time Some of 
the time A little of 
the time None of the 
time 
15. Did your child feel sick and tired? 1 2 3 4 
16. Were your child full of pep and energy?  1 2 3 4 
17. Did pain or discomfort interfere with your 
child's activities? 1 2 3 4 
 
 
During the last week , has it been easy or hard for your child to:      
(Circle one response on each line.)      
  Easy A little hard Very hard Can't do 
at all Too young for 
this activity 
18. Run short distances? 1 2 3 4 5 
19. Bicycle or tricycle? 1 2 3 4 5 
20. Climb three flights of stairs?  1 2 3 4 5 
21. Climb one flight of stairs? 1 2 3 4 5 
22. Walk more than a mile? 1 2 3 4 5 
23. Walk three blocks? 1 2 3 4 5 
24. Walk one block? 1 2 3 4 5 
25. Get on and off a bus? 1 2 3 4 5 
  
26.  How often does your child need help from another person for walking and climbing? (Circle one response.)   
1    Never 2    Sometimes 3    About half the time 4    Often  5    All the time 
  
27.  How often does your child use assistive devices (such as braces, crutches, or wheelchair) for walking and 
climbing? (Circle one response.)  
 
1    Never 2    Sometimes 3    About half the time 4    Often  5    All the time 
  
During the last week
, has it been easy or hard for your child to: 
(Circle one response on each line.)   
  Easy A little hard Very hard Can't do 
at all Too young for 
this activity 
28. Stand while washing his/her hands and face 
at a sink? 1 2 3 4 5 
29. Sit in a regular chair without holding on? 1 2 3 4 5 
30. Get on and off a toilet or chair? 1 2 3 4 5 
31. Get in and out of bed? 1 2 3 4 5 
32. Turn door knobs? 1 2 3 4 5 
33. Bend over from a standing position and pick up something off the floor? 1 2 3 4 5 
 
Pediatric Outcomes Instrument: Page 6 of 8 Pediatric Health Assessment (parent-re ported) 
 
34. How often does your child need help from another person for sitting and standing? (Circle one response.)  
 
1    Never 2    Sometimes 3    About half the time 4    Often  5    All the time 
 
 
35. How often does your child use assist ive devices (such as braces, crutch es, or wheelchair) for sitting and 
standing? (Circle one response.) 
 
1    Never 2    Sometimes 3    About half the time 4    Often  5    All the time 
 
 
36. Can your child participate in  recreational outdoor activities  with other children the same age?  
(For example: bicycling, tricycling, skati ng, hiking, jogging)  (Circle one response.)  
 
1    Yes, easily 2    Yes, but a little hard 3    Yes, but very hard 4    No 
 If you answered â€œnoâ€ to Question 36 above, was your child's activity limited by: (Circle yes to all that apply)     Yes 
37. Pain? 1 
38. General Health? 1 
39. Doctor or parent instructions? 1 
40. Fear the other kids wonâ€™t like him/her? 1 
41. Dislike of recreational outdoor activities? 1 
42. Too young? 1 
43. Activity not in season? 1 
  44. Can your child participate in pickup games or sports with other children the same age?  
(For example: tag, dodge ball, basketball, soccer, catch, jump rope, touch football, hop scotch)   
(Circle one response.)  
 
1    Yes, easily 2    Yes, but a little hard 3    Yes, but very hard 4    No 
 
If you answered â€œnoâ€ to Question 44 above, was your child's activity limited by: (Circle yes to all that apply)  
 
  Yes 
45  Pain? 1 
46. General Health? 1 
47. Doctor or parent instructions? 1 
48. Fear the other kids wonâ€™t like him/her? 1 
49. Dislike of pickup games or sports? 1 
50. Too young? 1 
51. Activity not in season? 1 
 
 
 
Pediatric Outcomes Instrument: Page 7 of 8 Pediatric Health Assessment (parent-re ported) 
52.  Can your child participate in competitive level sports  with other children the same age? 
(For example: hockey, basketball, soccer, football, baseball, swimming, running [track or cross country], 
gymnastics, or dance) (Circle one response.)  
 
1    Yes, easily 2    Yes, but a little hard 3    Yes, but very hard 4    No 
 
If you answered â€œnoâ€ to Question 52 above, was your child's activity limited by: (Circle yes to all that apply)     Yes 
53. Pain? 1 
54. General Health? 1 
55. Doctor or parent instructions? 1 
56. Fear the other kids wonâ€™t like him/her? 1 
57. Dislike of pickup games or sports? 1 
58. Too young? 1 
59. Activity not in season? 1 
  
60. How often in the  last week
 did your child get together and do things with friends? (Circle one response.)  
 
1    Often 2    Sometimes 3    Never or rarely 
 
If you answered â€œsometimesâ€ or â€œnever or rarelyâ€ to Question 60 above , was your child's activity limited by: 
(Circle yes to all that apply)    Yes 
61. Pain? 1 
62. General Health? 1 
63. Doctor or parent instructions? 1 
64. Fear the other kids wonâ€™t like him/her? 1 
65. Friends not around? 1 
 
 
66. How often in the last week
 did your child participate in gym/recess ? (Circle one response.)  
 
1    Often 2    Sometimes 3    Never or rarely 4    No gym or recess 
 
If you answered â€œsometimesâ€ or â€œnever or rarelyâ€ to Question 63 above , was your child's activity limited by: 
(Circle yes to all that apply)  
  Yes 
67. Pain? 1 
68. General Health? 1 
69. Doctor or parent instructions? 1 
70. Fear the other kids wonâ€™t like him/her? 1 
71. Dislike of gym/recess? 1 
72. School not in session? 1 
73. Does not attend school? 1 
 
74.  Is it easy or hard for your child to make friends with children his/her own age? (Circle one response.)  
 
1  Usually easy 2    Sometimes easy 3    Sometimes hard 4    Usually hard 
 
Pediatric Outcomes Instrument: Page 8 of 8 Pediatric Health Assessment (parent-re ported) 
75. How much pain has your child had during the last week ? (Circle one response.)  
 
1  None 2    Very mild 3   Mild 4   Moderate 5   Severe 6   Very severe 
 
 
76. During the  last week , how much did pain interfere with your child's normal activities  (including at home, 
outside of the home, and at school)?  (Circle one response.)  
 
1    Not at all 2    A little bit 3    Moderately 4    Quite a bit  5    Extremely 
 
 
 
What expectations do you have for your child's treatment? 
As a result of my child's treatment, I expect my child: (Circle one response on each line.)  
  Definitely 
yes Probably 
yes Not sure Probably 
not Definitely 
not 
77. To have pain relief. 1 2 3 4 5 
78. To look better. 1 2 3 4 5 
79. To feel better about himself/herself. 1 2 3 4 5 
80. To sleep more comfortably. 1 2 3 4 5 
81. To be able to do activities at home. 1 2 3 4 5 
82. To be able to do more at school. 1 2 3 4 5 
83. To be able to do more play or 
recreational activities (biking, walking, 
doing things with friends).  1 2 3 4 5 
84. To be able to do more sports. 1 2 3 4 5 
85. To be free from pain or disability as an 
adult.  1 2 3 4 5 
 
 
86.  If your child had to spend the rest of his/ her life with his/her bone and muscle condition as it is right now , 
how would you feel about it? (Circle one response.)  
 
1    Very satisfied 2    Somewhat satisfied 3    Neut ral  4    Somewhat dissatisfied  5    Very dissatisfied 
 
Clinical Trial  Protocol  CAT -1004-301 
Summary  of Changes                   16 April  2020   
Protocol Title: A Randomized, Double -Blind, Placebo -Controlled, Global Phase  3 
Study of Edasalonexent in Pediatric Patients with Duchenne 
Muscular Dystrophy  
Protocol Number: CAT -1004-301 
Original Version Date : 09 July 2018 
Amendment :  1 
Summary and Rationale for Changes 
The following information summarizes the changes captured in Amendment 1 reflective of 
study conduct during the COVID-19 pandemic:  
â€¢ As patients may not be able to come on -site for visits or for a reduced amount of time, 
modifications have been made to the original study procedures and schedule of assessments to reduce the patientâ€™s risk or exposure to COVID -19 for Week 39 and 
Week 52 study visits. These include:  
o Allowance for the Week 52 visit to be conduct ed out of  the visit window (but 
in no case should the projected target date be changed by more than 2 months ). 
o Ability to perform study procedures either on site or remotely by using 
alternative approaches to collect study assessments. 
o As the top priority is safety, assessing for AE and concomitant medications is 
the highest priority to continue, which will occur remotely at intervals. 
o Based on the safety profile of edasalonexent to date, and consideration that all patients in this study have been on study drug for 6 months, other safety 
assessments, including physical examinations, chemistry and hematology labs 
and urinalysis can be deferred for six- month intervals if not feasible . 
o Drug dispensation can take place according to local site procedures, including secured, temperature -controlled shipments to the patientsâ€™ homes 
o A prioritized list of assessments has been included in Appendix 2 of the 
protocol.  
â€¢ Clarification that post the COVID -19 pandemic, clinical monitoring may resume with 
more intense pace to clean all data accumulated.   
 
 